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ABSTRACT 
Cancer is associated with many molecular aberrations that support the malignant 
phenotype. In that regard, aberrant activation of epidermal growth factor receptor 
(EGFR), Src, and signal transducer and activator of transcription 3 (Stat3) occur 
concurrently in pancreatic cancer and are implicated in the disease phenotype. 
Notwithstanding, increasing evidence indicates that therapies that target only EGFR or 
Src are rather ineffective in modulating the cancer phenotype. The poor therapeutic 
outcome of the monotherapies targeting EGFR or Src may in part be due to the 
increased incidence of signaling cross-talks among aberrant signaling pathways in 
cancer. Molecular details of the signaling integration between EGFR, Src and Stat3, 
however, are lacking. Understanding how the aberrant EGFR, Src and Stat3 pathways 
are integrated in pancreatic cancer would facilitate the design of effective multiple-
targeted, clinically feasible therapeutic modalities. Our study shows that in pancreatic 
cancer cell lines, aberrant Src activity promotes abnormal EGFR activation through the 
phosphorylation of the EGFR motifs, Tyr845, Tyr1068 and Tyr1086. Furthermore, 
aberrantly-active EGFR and Src together induce constitutive activation of Stat3 in 
pancreatic cancer cells. Evidence further shows that EGFR, Src and Stat3 physically 
associated into a heteromeric complex. Significantly, the EGFR, Src and Stat3 
heteromeric complex is detectable in the nucleus and functions as a transcriptionally-
active complex to induce the c-Myc gene. Of therapeutic significance, the concurrent 
inhibition of Stat3 and EGFR or Src promoted greater viability loss and apoptosis of 
pancreatic cancer cells in vitro, and induced stronger tumor growth inhibition in 
xenografts of human pancreatic cancer. Altogether, our studies suggest that the 
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heteromeric EGFR, Src, and Stat3 complex may serve as an additional novel 
mechanism of support of the pancreatic cancer phenotype. Furthermore, our studies 
provide evidence that the concurrent targeting of Stat3 and EGFR or Stat3 and Src 
could be a more effective therapeutic approach for human pancreatic cancer. 
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INTRODUCTION 
Pancreatic cancer is one of the most lethal cancers. Nearly 37,680 new cases were 
diagnosed in 2008 and 34,290 deaths were reported. The one year relative survival is 
20% and the five year rate is 4%[1]. The low survival rates are attributable to the fact 
that fewer than 10% of patient tumors are confined to the pancreas[2]. The symptoms 
are nonspecific and include weight loss, dyspepsia, nausea, vomiting and fatigue. 
 
Not much is known regarding the etiological factors or the molecular mechanism behind 
the disease. Various signaling pathways have been linked to pancreatic cancer. K-ras 
mutation[3] and loss of p16[4] have been found in pancreatic cancer. Excessive 
activation of downstream signaling pathways such as Src, NFκB and Stat(signal 
transducer and activator of transcription)3 signaling pathways also occur[5]. These 
alterations enhance cancer cell proliferation, suppress pro-apoptotic effects and 
promote tumor spread and metastasis. There has been evidence of increased activity of 
growth factor receptors like epidermal growth factor, transforming growth factor, 
hepatocyte growth factor, vascular growth factor and fibroblast growth factor [6, 7]. Due 
to its significance, the epidermal growth factor receptor has been targeted for therapy 
against pancreatic cancer. 
 
The epidermal growth factor receptors are activated in various cancers and high 
expression of EGFR is associated with poor prognosis[8]. The induction of EGFR 
promotes cell division and survival through the mitogen-activated protein kinase (MAPK) 
cascade, the phosphotidylinositol-3-kinase (PI3K) pathway and the signal transducer 
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and activator of transcription (STAT) pathway. EGFR belongs to the family of receptor 
tyrosine kinase, containing an extracellular region (ectodomain) that binds to the 
polypeptide ligands (EGF, TGF-α), a single pass transmembrane helix and a 
cytoplasmic domain with tyrosine kinase activity[9]. Upon binding of the ligand to the 
extracellular domain, the receptor forms a homo/heterodimers, leading to 
autophosphorylation of specific tyrosine residues. The tyrosine residues Y992, Y1068, 
Y1086, Y1148, and Y1173 are the autophosphorylation sites that serve as the docking 
sites for SH2- and phosphotyrosine- containing signaling molecules [10]. EGFR 
associates with and is phosphorylated by other receptor tyrosine kinase. c-Src, a non-
receptor tyrosine kinase partly phosphorylates EGFR at the residues Y845, 
Y1101,Y992, Y1086[11-13]. EGFR and Src cooperate in both mitogenesis and 
transformation. Cellular Src functions as a co-transducer of various growth factor 
receptors[14]. c-Src regulates cell cycle progression, cell adhesion and stress 
responses. Src activation is shown to increase cell proliferation, cell migration and 
metastases [15-19]. Src is known to have a role in the production of pro-angiogenic 
factors such as VEGF[20]. EGFR and Src double expression increased MAPK activity 
and increased the number of aggressive tumors.  
 
The concurrent activation of EGFR and Src in various cancers is suggestive of a 
possible crosstalk between the signaling molecules. In pancreatic cancer, initial results 
suggest that the aberrant Stat3 levels can be linked to constantly active EGFR and Src. 
Stat3 is a member of STAT family of proteins. Stat3 activation is induced by the 
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phosphorylation on tyrosine 705 mediated by tyrosine kinases including EGFR, c-Src 
and the Janus Kinase (JAK). Moreover, phosphorylation on serine 727 is reported to 
enhance Stat3 transcriptional activity. The phosphorylation on the Tyr705 mediates the 
formation of active Stat3:Stat3 dimers, which translocates to the nucleus and induces 
the transcription of genes important for cell growth and proliferation, survival and 
immune responses. While normal STAT activation is transient in keeping with the 
normal cellular requirements, aberrant Stat3 activation occurs and is associated with 
malignant transformation and tumorigenesis. In the context of malignant transformation, 
persistent Stat3 activation occurs with the hyper-activation of the IL-6/gp-130 and JAK 
pathway, or elevated EGFR and Src levels. At the molecular level it is known that 
aberrant Stat3 causes expression changes of critical genes that deregulate cell cycle 
and cell growth. Constitutive Stat3 is associated with induction of Cyclin D1/Cyclin D2, 
c-Myc expression, down regulation of expression of cyclin dependent Kinase inhibitor; 
p21. There is also evidence that suggests that abnormal Stat3 activity promotes 
tumorigenesis by up regulating anti-apoptotic proteins like Bcl-xl, Bcl-2, and Mcl-1. 
Constitutive Stat3 activation also promotes angiogenesis via induction of VEGF; 
hypoxia-inducing factor and also facilitates tumor migration, invasion and 
metastasis[21]. Stat3 has been known to interact with EGFR through its SH2 domain to 
the phospho-Tyrosine 1068 and 1086 on EGFR[22].  
 
Our goal is thus to understand the interaction between EGFR, Src and Stat3 and to 
develop a molecular targeted therapy approach for the module as against for an 
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individual entity. Targeting EGFR alone or Src alone may not be sufficient and a 
combined therapy will provide a stronger basis to circumvent the diverse processes that 
promote and support the pancreatic cancer and progression of this disease. 
 
Gemcitabine, the most active cytotoxic drug in advanced disease shows an 
improvement in symptoms in 20-30% of patients and a 1 year survival of 18%[5]. The 
knowledge of the molecular mechanisms underlying pancreatic cancer may improve the 
management of patients and development of new therapies. Erlotinib, an orally 
available EGFR inhibitor, significantly improved the survival of patients and was 
approved as a first line therapy with Gemcitabine[5].  However targeting EGFR alone 
has not been very effective, since there are other receptor and non-receptor kinases 
that show aberrant activation. A combination therapy approach has been used to target 
EGFR along with other growth factor receptors.   
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ENHANCED SENSITIVITY OF PANCREATIC CANCER CELLS TO 
CONCURRENT INHIBITION OF ABERRANT STAT3 AND EGFR OR 
SRC 
 
 
 
EGFR, Src and Stat3 are known to be activated in pancreatic cancer. Targeting each of 
the proteins alone has not been very effective. A study of the correlation between the 
three proteins would help develop a better therapeutic approach for pancreatic cancer. 
The work here presents the mode of activation of the three proteins, their inter-
relationship and targeting multiple proteins to determine if a combinatorial approach has 
a better therapeutic value. 
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Introduction: 
Pancreatic cancer is a very lethal disease, with poor prognosis and mortality nearly 
identical to the rate of incidence. The disease also remains poorly understood. There 
are several genetic mutations and activated signal transduction proteins that occur 
during pancreatic ductal cell carcinogenesis. Understanding the critical molecular 
events that promote this disease and how they contribute to its maintenance and 
progression would facilitate the development of effective targeted therapeutic 
modalities. One of the major molecular abnormalities is the overexpression and/or 
activation of the epidermal growth factor receptor (EGFR) protein, with an incidence of 
30 to 50% of pancreatic cancer cases [23]. Evidence indicates that the hyperactive 
epidermal growth factor (EGF)/EGFR pathway is important in the disease maintenance 
and progression[24]. Similarly, overexpression of the c-Src tyrosine kinase occurs in a 
large percentage of pancreatic adenocarcinoma and is observed to increase EGFR 
activities during tumorigenesis[25-27]. The overactivity of the Src family kinases leads to 
deregulation of tumor cell growth and survival, disruption of cell-to-cell contacts, 
promotion of migration and invasiveness, and induction of tumor angiogenesis [27]. 
Another molecular abnormality prevalent in pancreatic cancer and implicated in the 
disease is aberrant signal transducer and activator of transcription 3 (Stat3) [27-30]. 
Stat3 is a member of the STAT family of cytoplasmic transcription factors. As with the 
other STATs, Stat3 requires extrinsic tyrosine phosphorylation to become activated, and 
this event is induced by growth factor receptors and cytoplasmic tyrosine kinases, such 
as Src and Janus kinase (Jaks) families[31]. In contrast to normal STAT signaling that is 
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transient in accordance with the requirements for normal biological processes, tumor 
cells harbor aberrant Stat3 activation, which compelling evidence indicates dysregulates 
cell growth and survival, promotes tumor angiogenesis and tumor cell migration and 
invasion, and induces tumor immune tolerance[32, 33].  
 
The concurrence of the hyperactive EGFR and Src tyrosine kinases, together with 
aberrant Stat3, in pancreatic cancer raises key questions about the contributory role of 
each entity to the disease. Deregulated signal transduction provides the framework for 
signaling cross-talk and functional cooperation that would not only support the 
malignant phenotype and the disease progression but also would influence drug 
responsiveness. Thus, a potential collaboration among hyperactive EGFR, Src, and 
Stat3 in support of the malignant phenotype and in regulating the response to 
monotargeted therapy is a reasonable model to propose. It is also a concept that would 
support the recent approval of the combined gemcitabine and EGFR inhibitor erlotinib 
for the treatment of pancreatic cancer patients[34]. An increased understanding of the 
integration, functional relationship, and the collective roles of the EGFR, Src, and Stat3 
in supporting pancreatic cancer is needed to derive effective, multiple-targeted 
therapeutic modalities for this disease. We provide evidence that the concurrent 
inhibition of aberrant Stat3 and EGFR or Src is effective in inducing antitumor cell 
responses in vitro and in inhibiting human pancreatic tumor growth in xenograft models.  
 
Materials and Methods 
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Cells and Reagents. 
v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), human pancreatic cancer (Panc-
1), and leukemic (K562) lines have been described[35-37]. The human pancreatic 
cancer lines Colo-357 and Mia-PaCa-2 were gifts from Drs. J. M. Lancaster and M. P. 
Malafa (Moffitt Cancer Center, Tampa, FL). The immortalized human pancreatic duct 
epithelial cell (HPDEC) line was obtained from Dr. M. S. Tsao (Ontario Cancer Institute, 
University Health Network/Princess Margaret Hospital, Toronto, ON, Canada)[38]. 
Except for the HPDEC line that was grown in keratinocytes/serum-free medium 
supplemented with 0.2 ng of EGF, 30 μg/ml bovine pituitary extract and containing 
antimycol, and the K562 line cultured in RPMI 1640 medium containing 10% heat-
inactivated fetal bovine serum and 100 units/ml penicillin/streptomycin, all other cell 
lines were grown in Dulbecco's modified Eagle's medium containing 5% iron-
supplemented bovine calf serum and 100 units/ml penicillin/streptomycin. Recombinant 
human EGF is from Creative Biolabs (Port Jefferson Station, NY), and gemcitabine is 
from Ely Lilly & Co. (Indianapolis, IN). Erlotinib, ZD1839 (ZD/Iressa), and dasatinib 
(Das) were purchased from ChemieTek (Indianapolis, IN).  
 
Nuclear Extract Preparation and Gel-Shift Assays. 
Nuclear extract preparation and DNA binding with electrophoretic mobility-shift assay 
(EMSA) were carried out as reported previously[35, 36]. The 32P-labeled oligonucleotide 
probes used were high affinity cis-inducible element from the c-fos gene (m67 variant, 
5′-AGCTTCATTTCCCGTAAATCCCTA) that binds Stat1 and Stat3 [39] and the 
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mammary gland factor element (from the bovine β-casein gene promoter, 5′-
AGATTTCTAGGAATTCAA) that binds Stat1 and Stat5[40, 41]. 
 
SDS-Polyacrylamide Gel Electrophoresis/Western Blot Analysis. 
Western blot analysis was performed as described previously[35, 42]. Primary 
antibodies used were anti-Stat3 (C20) (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), anti-pY845EGFR (Millipore Corporation, Billerica, MA), and antibodies against 
pY705Stat3, Stat3, pY1068EGFR, pY1086EGFR, pY1173EGFR, EGFR, pY416Src, 
Src, c-Myc, and β-actin (Cell Signaling Technology Inc., Danvers, MA).  
 
Small-Interfering RNA Transfection. 
Small-interfering RNA (siRNA) sequences for EGFR and Src were ordered from 
Dharmacon RNAi Technologies, Thermo Scientific (Lafayette, CO). Sequences used 
were: EGFR sense strand, 5′-GAAGGAAACUGAAUUCAAAUU-3′; EGFR antisense 
strand, 5′-pUUUGAAUUCAGUUUCCUUCUU-3′; control siRNA sense strand, 5′-
AGUAAUACAACGGUAAAGAUU-3′; and control siRNA antisense strand, 5′-
pUCUUUACCGUUGUAUUACUUU-3′. The c-Src SMARTpool siRNA reagent (NM-
005417; Millipore Corporation) was used for Src. Transfection into cells was performed 
using 20 nM EGFR siRNA or 25 nM Src siRNA and 8 μl of Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA) in OPTI-MEM culture medium (Invitrogen).  
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Cell Proliferation Assay and Propidium Iodide Staining or Annexin V Binding with 
Flow Cytometry. 
Proliferating cells in 6- or 96-well plates were treated once with 0.1 to 1 μM Iressa, 100 
nM Das, 50 to 100 μM S3I-201, 1 μM gemcitabine, or combinations of inhibitors for up 
to 96 h. Viable cells were counted by trypan blue exclusion/phase-contrast microscopy 
or assessed by the CyQuant cell proliferation assay according to the manufacturer's 
instructions (Invitrogen), or cells were stained with propidium iodide for 30 min or 
subjected to annexin V binding (BD Biosciences, San Jose, CA) and analyzed by flow 
cytometry for cell cycle distribution or apoptosis, respectively. 
Colony Survival Assay. 
Single-cell suspension of Panc-1 and Colo-357 cells were seeded in 6-cm dishes (500 
cells/dish) and assayed as reported previously [43]. Briefly, single-cell suspension of 
Panc-1 and Colo-357 cells were seeded in 6-cm dishes (500 cells/well), treated the next 
day with inhibitors for 48 h, and allowed to grow until large colonies were visible. 
Colonies were stained with crystal violet for 4 h and counted under a phase-contrast 
microscope.  
Cell Migration and Matrigel Invasion Assays. 
Cell migration and invasion experiments were carried out and quantified as described 
previously[44] using Bio-Coat migration chambers (BD Biosciences, Franklin Lakes, NJ) 
of 24-well companion plates with cell culture inserts containing 8-μm pore size filters, 
according to the manufacturer's protocol.  
Mice and in Vivo Tumor Studies. 
Studies with mice were performed under approved Institutional Animal Care and Use 
Committee procedures and guidelines. Six-week-old female athymic nude mice were 
purchased from Harlan (Indianapolis, IN) and maintained in the institutional animal 
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facilities approved by the American Association of Accreditation of Laboratory Animal 
Care. Athymic mice were inoculated (subcutaneously) in the left flank area with Colo-
357 cells (3 × 106) in 100 μl of 1× phosphate-buffered saline or Panc-1 cells (8 × 106) in 
100 μl of 1:1 (v/v) DMEM/Matrigel (Basement Membrane Matrix; BD Biosciences) 
suspension. Animals were monitored daily after inoculation. For Colo-357 cells, tumors 
of 60 mm3 were established after 4 to 6 days, whereas tumors developed in Panc-1 
cells took 10 to 15 days to reach 100 mm3. Animals were grouped so that mean tumor 
sizes in all the groups were nearly identical. For the xenografts developed with the Colo-
357 line, tumor-bearing mice were given ZD (75 mg/kg i.v.), Das (15 mg/kg i.v.), or S3I-
201 (5 mg/kg i.v.) alone or in combination every 2 or 3 days for the first 2 weeks and 
daily for 5 days each week for the next 3 weeks. Mice bearing tumors developed using 
Panc-1 cells were given ZD (75 mg/kg i.v.), Das (15 mg/kg i.v.), or S3I-201 (5 mg/kg 
i.v.) alone or in combination every 3 to 5 days, or erlotinib (5 mg/kg i.v., every day) in 
combination with gemcitabine (100 mg/kg i.v., every 3 days) for 48 days. The doses and 
the treatment schedules used were inferred from literature reports. Tumor sizes were 
measured by calipers every 2 or 3 days and converted to tumor volumes by the formula 
V = 0.52 × a2 × b, where a is the smallest superficial diameter and b is the largest 
superficial diameter. In addition, at the conclusion of the studies, weights of mice were 
recorded. For each treatment group, the tumor volumes for each set of measurements 
were statistically analyzed and compared with the control (nontreated) group.  
Statistical and Data Analyses. 
Statistical analysis was performed on mean values using Prism software (GraphPad 
Software, Inc., San Diego, CA). Cell proliferation data and effect of drug combinations 
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were analyzed with CalcuSyn software (Biosoft, Cambridge, UK) to determine additive 
or synergistic effects. The significance of differences between groups was determined 
by the paired t test at *, p < 0.05; **, p < 0.01; and ***, p < 0.001.  
 
Results 
Aberrant EGFR, Src, and Stat3 in Pancreatic Cancer Lines. 
Consistent with published reports[28, 29, 44], Stat3 activity, per DNA binding with 
EMSA analysis in nuclear extract preparations, is constitutive in Panc-1 and Colo-357, 
low in Mia-Paca-2, and undetectable in the normal HPDEC compared with aberrant 
levels in NIH3T3/v-Src[35] (Fig. 2Ai). Per supershift analysis, the DNA–protein complex 
contains Stat3 (Fig. 2Ai, lane 3). No Stat5 activity is detectable in pancreatic cancer 
cells (Fig. 2Aii) compared with aberrant levels in the K562 leukemic cells [37]. Similarly, 
immunoblotting analysis showed pY416c-Src levels are moderate in Mia-Paca-2 but 
elevated in Panc-1 and Colo-357 cells as reported previously[24, 27] and similar to the 
levels in NIH3T3/v-Src compared with low levels in HPDEC (Fig. 2B, top). The elevated 
pY416Src levels parallel the enhanced levels of the Src-sensitive pY845EGFR motif[26] 
in Panc-1 and Colo-357 cells compared with low levels of the same in HPDEC (Fig. 2B, 
bottom). The total Src or EGFR protein remained unchanged. Immunoblotting analysis 
further showed enhanced EGFR autophosphorylation motifs[45], pY1068EGFR (Fig. 
1Ai, lanes 2 and 7), pY1086EGFR (Fig. 1Aii, lanes 2 and 7), and pY1173EGFR (Fig. 
1Aiii, lanes 2 and 7) in Panc-1 and Colo-357 compared with basal levels of the same in 
HPDEC (Fig. 1Ai–iii, lane 1).  
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Functional Integration of EGFR and Src in Pancreatic Cancer Cells. 
We examined the functional relationship between the activated EGFR and Src. 
Immunoblotting analysis showed treatment of cells with Das inhibited Src activity 
(pY416Src)[46] and induced an early (1 h) and a sustained (24 h) decrease in 
pY845EGFR levels (Fig. 1Bi). By contrast, no detectable changes in pY416Src and 
pY845EGFR levels were induced by treatment with the pan-ErbB inhibitor, PD169540 
(PD169)[47] (data not shown) or the selective EGFR inhibitor, ZD[48] (Fig. 1Bi). In 
confirmation, the siRNA knockdown of c-Src abrogated pY845EGFR levels (Fig. 1Bii, 
Src siRNA), whereas the EGFR knockdown by siRNA had minimal effect on pY416Src 
levels (Fig. 1Biii, EGFR siRNA). Scrambled siRNA (con siRNA) has no effect (Fig. 1B, ii 
and iii, con siRNA). Thus, elevated pY845EGFR levels in pancreatic cancer cells are 
sensitive to Src activity.  
 
Immunoblot analysis further showed that the treatment of Panc-1 and Colo-357 cells 
with ZD decreased pY1173EGFR levels (Fig. 1Aiii, lanes 3, 4, 8, and 9) by as early as 1 
h and up to 24 h, with no effect on pY1068EGFR (Fig. 1Ai, lanes 3, 4, 8, and 9) or 
pY1086EGFR levels (Fig. 1Aii, lanes 3, 4, 8, and 9), suggesting that the EGFR kinase is 
essential for the induction of pY1173EGFR but not of pY1068EGFR or pY1086EGFR. 
By contrast, Das treatment decreased pY1068EGFR and pY1086EGFR levels (Fig. 1A, 
i and ii, lanes 5, 6, 10, and 11) with minimal effect on pYEGFR1173 levels (Fig. 1Aiii, 
lanes 5, 6, 10, and 11). Thus, Src activity additionally promotes pY1068EGFR and 
pY1086EGFR in pancreatic cancer cells.  
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Figure 1:Immunoblotting analyses of Stat3, Src and EGFR activities for effects of inhibitors.   
A and B, immunoblotting analysis of whole-cell lysates from cells untreated or treated with ZD or Das (Ai) 
or transfected with or without c-Src siRNA (Aii), EGFR siRNA (Aiii), or scrambled siRNA control (con) and 
probing for pY416c-Src (pY416Src), Src, pY845EGFR, and EGFR; and untreated or treated with ZD or 
Das and probing for pY1068EGFR (Bi), pY1086EGFR (Bii), and pY1173EGFR (Biii), and EGFR. Data are 
consistent with those obtained from four independent experiments. 
 
Fig :1 
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Figure 2: EMSA and immunoblot of activated Stat3, Stat5, pY416Src and pY845EGFR  
A. (i) EMSA analysis of Stat3 binding activity in Panc-1, NIH3T3/v-Src, HPDEC, Mia-Paca-2, Colo-357 (ii) 
EMSA analysis of Stat5 binding activity in K562 , NIH3T3/v-Src, HPDEC, Colo-357, Mia-paca-2, Panc-1. 
B. Immunoblot analysis of pY416Src, Src, pY845EGFR,EGFR in NIH3T3/v-Src, HPDC, Mia-Paca-2, 
Panc-1 and Colo357 cell lines. 
  
Fig :2 
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EGFR and Src Promote Aberrant Stat3 Activation but Do Not Induce ErkMAPK or 
Akt Activity.  
Both pY1068EGFR and pY1086EGFR levels are binding sites for Stat3 [22]. Given the 
concurrent EGFR and Src activation in Panc-1 and Colo-357 cells, we sought to define 
the regulation of aberrant Stat3 activation. By in vitro DNA-binding assay with EMSA 
analysis of nuclear extract preparations, we observed an early repression (in the first 30 
min to 1 h of treatment) of constitutively active Stat3 by the pan-ErbB inhibitor, PD169, 
the ErbB2-selective inhibitor, AG879[28], ZD, or Das (3Ai, lanes 4, 5, 7, and 8, Aii, lanes 
2, 4, 6, and 11, and B, 1 h), or by a combined PD169 and Das (Fig. 3Ai, lanes 10 and 
11 and Aii, lane 8). However, the Stat3 activity in Panc-1 cells consistently rebounded 
after 24-h treatments with Das, ZD, or PD169 (Fig. 3A, i and ii, 24 h), even though 
EGFR or Src activity remained inhibited (Fig. 1, 24 h). Twenty-four-hour treatment with 
the AG879 moderately inhibited Stat3 activity (Fig. 3Aii, lane 12), which we speculate 
may be because of its widespread activity as a pan-ErbB inhibitor. By contrast, 
treatment with the Jak inhibitor AG490 for 1 h had no effect on constitutive Stat3 activity 
but abolished Stat3 activity at 24-h treatment (Fig. 3Aii, lanes 9 and 10). Moreover, the 
combined treatment with AG490 and ZD, Das, or PD169 for 24 h abolished 
constitutively active Stat3 (Fig. 3Aii, lanes 14–16) and prevented the previously 
observed rebound of Stat3 activity. In Colo-357, Stat3 activity was inhibited by ZD and 
Das, with the effect more striking for Das (Fig. 3B). These findings together reveal a 
constitutive Stat3 activation in pancreatic cancer cells that is mediated by both EGFR 
and Src, with a compensatory, long-term Jak-dependent Stat3 activation, a pattern 
similarly observed in head and neck squamous carcinoma, mesothelioma, squamous 
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cell skin carcinoma, and non–small cell lung cancer cell lines after the inhibition of 
Src[49]. Data also show that the concentration of S3I-201 (50 μM) used in the studies 
sufficiently inhibits aberrant Stat3 activation in Panc-1 and Colo-357 cells (Fig. 2C). In 
further support, the siRNA knockdown of EGFR (EGFR siRNA) or Src (Src siRNA) led 
to pStat3 suppression, as assayed by immunoblotting analysis (Fig. 3D), with no effect 
of scrambled siRNA (con). We confirm that treatment of Panc-1 cells with S3I-201 for 24 
h inhibits aberrant Stat3 activity in a dose-dependent manner (Fig. 3Ai, lanes 13–16).  
In contrast to the effects on Stat3 activity, immunoblotting analysis showed elevated 
pErk1/pErk2MAPK and pAkt activities in Panc-1 and Colo-357 cells, which were not 
responsive to ZD or Das treatment (Fig. 4), suggesting that aberrant EGFR and Src 
kinases do not promote the baseline elevated ErkMAPK and Akt activities in pancreatic 
cancer cells. Thus, Erk and Akt are not key mediators of EGFR and Src functions in 
pancreatic cancer.  
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Figure 3: EMSA and immunoblotting analyses for effects of inhibitors on Stat3 activation. 
EMSA analysis of Stat3 DNA-binding activity in Panc-1 (A) or Colo-357 (B) cells treated or untreated with 
the pan ErbB inhibitor PD169, ZD, Das, the Jak inhibitor AG490, the ErbB2- selective inhibitor AG879, or 
inhibitor combinations for the indicated times, or Panc-1 and Colo-357 cells treated for 24 h with S3I-201 
(C), or immunoblotting analysis of whole-cell lysates from Panc-1 cells transfected with EGFR siRNA, Src 
siRNA, or scrambled siRNA (control) and probing for pStat3 or Stat3 (D).*, supershift analysis. Data are 
consistent with those obtained from three independent experiments. 
  
Fig:3 
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Figure 4: Immunoblotting analyses for effects of inhibitors on pERK1/2 and pAkt 
Immunoblot analysis in Panc-1 cells and Colo-357 cells treated (for 1h or 24h) or untreated and probing 
for  (i) pERK1/2, ERK1/2, and (ii) pAkt, Akt 
  
Fig:4 
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Inhibition of Stat3 Sensitizes Pancreatic Cancer Cells to Effects of EGFR and Src 
Inhibitors. 
We investigated the biological and therapeutic implications of the unique inter-
relationship between EGFR, Src, and Stat3 activation. Das and ZD were used at 100 
nM and 0.1 to 1 μM, respectively, as in the literature reports [46, 47], whereas the Stat3 
inhibitor S3I-201 was used at the suboptimum, 50 μM, or at the 100 μM required to 
inhibit Stat3 activation[21]. Cell growth was measured as viable cell count by trypan 
blue exclusion/phase-contrast microscopy. Cells treated with 1 μM ZD, 100 nM Das, or 
50 μM S3I-201 alone for 24 h showed minimal effect on growth (Fig. 5A, day 1). 
Treatment for 48 to 96 h with Das or S3I-201 alone appeared to slow down cell growth, 
whereas treatment for the same period with ZD showed minimal effect (Fig. 5A, i and ii, 
days 2–4). The concurrent treatment with both S3I-201 and ZD or S3I-201 and Das for 
24 h seemed to decrease growth (Fig. 5A, day 1). By contrast, the concurrent treatment 
with both S3I-201 and ZD or S3I-201 and Das for 48 to 96 h induced larger decreases 
in the number of viable cells (Fig. 5A, days 2–4). These data were confirmed by the 
CyQuant cell proliferation assay (Invitrogen). The CyQuant assay showed that, to some 
extent, the 48-h treatment with each inhibitor alone decreased cell growth in a dose-
dependent manner (Fig. 5B, ZD, Das, and S3I-201). However, the observed effects of 
any single agent were significantly weaker than the effects of the concurrent treatment 
with a Stat3 inhibitor and an inhibitor of EGFR or Src. Thus, treatment with 50 μM S3I-
201 increased the sensitivity of Panc-1 and Colo-357 cells to ZD and Das, shifting the 
dose-response curves to the left (Fig. 5B, ZD + S3I-201 and Das + S3I-201; insert 
shows the effect of 50 μM S3I-201 alone on growth). Cotreatment with S3I-201 
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significantly decreased the IC50 values from 17 to 0.4 μM and 100 to 6 nM, respectively, 
for ZD and Das against Panc-1 growth (Fig. 5B, i and ii), and from 6.5 to 2.4 μM and 90 
to 8 nM, respectively, for ZD and Das against Colo-357 growth (Fig. 5B, iv and v). 
Analysis, per Chou and Talalay equation, using CalcuSyn (Biosoft) indicated synergism 
for the combination of S3I-201 and ZD and S3I-201 and Das, with combination indexes 
of <1. The CyQuant cell proliferation assay also showed that Das but not ZD increased 
the sensitivity of both cell lines to S3I-201, decreasing the IC50 value from 40 to 15 μM 
and 45 to 20 μM, respectively, for effects on Panc-1 and Colo-357 cells (Fig. 5B, iii and 
iv). Thus, treatment with S3I-201 sensitized pancreatic cancer cells to ZD and Das.  
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Figure 5:Cell proliferation and viability studies for the effects of inhibitors 
A, trypan blue exclusion/phase-contrast microscopy for viable Panc-1 or Colo-357 cells after treatment for 
0 to 96 h with 1 μM ZD, 100 nM Das, or 50μM S3I-201, or combinations. B, CyQuant cell proliferation 
assay for the viability of Panc-1 (left) or Colo-357 (right) cells in response to 48-h treatments with the 
designated concentrations of ZD, Das, and S3I-201, alone and in combinations. Values, mean and S.D. n 
= 4 experiments, each in triplicate. 
  
Fig:5 
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Given the potential that the concurrent treatment with agents slowed down growth of 
pancreatic cancer cells, propidium iodide staining with flow cytometry was performed for 
cell cycle profile analysis. Treatment of Panc-1 or Colo-357 cells with ZD, Das, or S3I-
201 alone for 24 h had no significant impact on the cell cycle distribution, with nearly 
identical distribution at G0/G1, S, and G2/M phases as in the control, dimethyl sulfoxide-
treated cells (Fig. 6A, ZD, Das, and S3I-201). Similarly, the combined treatment with 
S3I-201 and ZD or S3I-201 and Das for 24 h appeared to have no dramatic effect on 
the cell cycle distribution of Colo-357 cells (Fig. 6Aii). For Panc-1, a noticeable decrease 
in the population in the S phase, with no dramatic increase in G0/G1, and an increased 
sub-G0 population occur in response to the combined treatment with ZD and S3I-201 or 
Das and S3I-201 (Fig. 6Ai, ZD + S3I and Das + S3I). We deduce that the combined 
treatment with the inhibitors of Stat3 and Src or EGFR induces some degree of 
apoptosis in Panc-1 cells at 24 h, with no dramatic change in the cell cycle profile in 
Colo-357 cells.  
 
Given the clinical implications of these findings, we extended these studies to examine 
the effect of inhibitors of the EGFR, Src, and Stat3 pathway on the sensitivity of 
pancreatic cancer lines to gemcitabine, the antimetabolite agent used for treating 
pancreatic cancer. The rationale for this study is the approval of erlotinib and 
gemcitabine combination therapy for locally advanced metastatic pancreatic cancer. 
CyQuant cell proliferation studies showed that inhibition of EGFR, Src, or Stat3 alone 
did induce some sensitization of Panc-1 and Colo-357 cells to gemcitabine (Fig. 6B). 
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More importantly, the combined inhibition of Stat3 and EGFR or Src induced a higher 
sensitization of cells to gemcitabine (Fig. 6B), further supporting the ability to 
substantially suppress the malignant phenotype by the combined inhibition of Stat3 and 
EGFR or Src.  
 
To further explore the sensitization potential of Stat3 inhibitors, we performed colony 
survival assay[43] . Generally, colonies were formed by day 21 after the single, 48-h 
treatment, and there were no differences between control (untreated) and treated 
samples in the length of time to form colonies and the sizes of colonies. Panc-1 cells 
showed decreased sensitivity to inhibitors, and the treatment with single inhibitors had 
minimal effect on colony numbers compared with the combined treatment with S3I-201 
(S3I) and Das or S3I-201 and ZD (Fig. 6Ci). Colo-357 cells were less sensitive to Das or 
ZD but showed a high sensitivity to S3I-201 and the combined S3I-201 and Das or ZD 
(Fig. 6Cii). Except for the Colo-357 response to S3I-201, overall the results indicate that 
Panc-1 and Colo-357 cells are more sensitive to the concurrent treatment with S3I-201 
and Das or S3I-201 and ZD. Furthermore, annexin V binding/flow cytometric analysis 
showed higher percentages of Panc-1 and Colo-357 cells undergo apoptosis in 
response to the concurrent inhibition of Stat3 and EGFR or Src than to the treatment 
with any single agent alone. Treatment of Panc-1 and Colo-357 cells with S3I-201, ZD, 
or Das alone induced lower percentage of apoptosis (Fig. 6D, ii and iii). By contrast, 
combined treatment with S3I-201 and Das or S3I-201 and ZD induced apoptosis in both 
Panc-1 and Colo-357 cells at 24 h and a higher percentage of apoptosis at 48 h (Fig. 
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6D, ii and iii). Panc-1 cells showed higher sensitivity to the combined treatment with S3I-
201 and ZD or Das, with up to 60% apoptosis, compared with 25% apoptosis in Colo-
357 cells (Fig. 6D, ii and iii). Similar results were obtained for the concurrent treatments 
with AG490 and ZD or Das (Fig. 6D, ii and iii), whereas similar treatments of normal 
HPDEC cells showed no significant apoptosis in response to combination treatments 
(Fig. 6Di). Altogether, our findings indicate that pancreatic cancer cells have a higher 
sensitivity to the combined inhibition of Stat3 and EGFR or Stat3 and Src than to the 
inhibition of a single entity.  
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Figure 6: Cell cycle distribution, cell gowth and colony survival and apoptosis studies for the 
effects of inhibitors 
Fig 6 
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A, cells were untreated (control) or treated with ZD (1 μM), Das (100 nM), S3I-201 (50 μM), ZD +S3I-201, 
or Das +S3I-201 for 24 h, stained with propidium iodide, and analyzed by flow cytometry for cell cycle 
distribution. B, CyQuant cell proliferation assay for the viability of Panc-1 (i) and Colo-357 (ii) cells after 
treatments for 48 h with the designated concentrations of ZD, Das, S3I-201, and gemcitabine (Gem), 
alone and in combinations. C, number of colonies emerging from cells in culture (500/6-cm dish) 
untreated or treated once with ZD, Das, S3I- 201 (S3I), or combinations and allowed to culture. D, 
annexin V binding/flow cytometry analysis of normal HPDEC, Panc-1, or Colo-357 cells treated or 
untreated with inhibitors or combinations. Values, mean and S.D. n = 4 experiments each in triplicate. *, p 
<0.05; **, p <0.01; ***, p < 0.001. 
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EGFR, Src, and Stat3 Together Promote Pancreatic Cancer Cell Migration and 
Invasion. 
Consistent with roles for Src and Stat3 in tumor cell motility, migration, invasion, and 
metastasis[27, 46]; in vitro Matrigel assay showed that Das or S3I-201 alone 
suppresses migration and invasion (Fig. 7A). However, the concurrent inhibition for 24 h 
of Stat3 and EGFR or Src induced stronger effects on Colo-357 migration and Panc-1 
invasion, except for the similar effect of Src inhibition on Panc-1 migration (Fig. 7A). At 
the 24-h treatment when these studies were done, there is no significant effect on the 
growth of Panc-1 and Colo-357 cells (Fig. 5), although for Panc-1 cells, cell cycle 
analysis revealed some evidence of increased sub-G0 population after 24-h treatment 
with ZD and S3I-201 or Das and S3I-201 (Fig. 6Ai), which may contribute to the 
reduced number of migrating Panc-1 cells.  
 
EGFR, Src, and Stat3 Module Regulates c-Myc Overexpression in Pancreatic 
Cancer Cells. 
For insight into the underlying molecular mechanisms, we studied the regulation of key 
cancer-relevant genes and observed that c-Myc is overexpressed in pancreatic cancer 
lines compared with normal HPDEC, and its expression was consistently more 
responsive to the 24-h treatment with both S3I-201 and ZD or S3I-201 and Das than the 
inhibition of Stat3, Src, or EGFR alone (Fig. 7B). These data raise the potential that 
Stat3, EGFR, and Src functionally cooperate to induce c-Myc overexpression in 
pancreatic cancer cells.  
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Figure 7: Concurrent inhibiton of Stat3 and EGFR or Src inhibits migration and invasion and 
suppresses c-Myc expression 
A, effects of 24-h treatment with ZD, Das, and/or S3I-201 (S3I) on migration and invasion. B, 
immunoblotting analysis of whole-cell lysates for c-Myc and β-actin expression in Panc-1 cells after 
treatment with inhibitors for 24 h. Values, mean and S.D. n = 3 or 4 experiments each in triplicate. *, p 
<0.05; **, p< 0.01; ***, p <0.001. 
  
Fig 7 
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Concurrent Inhibition of Stat3 and EGFR or Src Inhibits Human Pancreatic Tumor 
Growth in Xenografts. 
Subcutaneous xenografts of Colo-357, a metastatic pancreatic adenocarcinoma line, 
and the epithelioid carcinoma, Panc-1, line were used to study the therapeutic 
implication of the Stat3, EGFR, and Src inter-relationships and evaluate the in vivo 
antitumor effects of concurrent inhibition of Stat3 and EGFR or Src. Data showed that, 
in general, xenografts of Colo-357 cells showed low responsiveness to treatment with 
inhibitor of EGFR, Src, or Stat3 alone, although as the therapy progressed, tumors 
treated with only one inhibitor alone appeared to show reduced growth, which was 
statistically not significant from control, nontreated tumors (Fig. 8A). On the other hand, 
xenografts of Panc-1 cells showed greater sensitivity to the Src or the Stat3 inhibitor, 
which induced significant (p < 0.05) inhibition of tumor growth (Fig. 8B, Das and S3I-
201). Importantly, for both Colo-357 and Panc-1 lines, xenograft tumors were much 
more sensitive to the combined inhibition of Stat3 and EGFR or Stat3 and Src than to 
the inhibition of either one alone, with tumors consistently showing reduced growth and 
smaller sizes in response to the combined treatment throughout the entire study (Fig. 8, 
ZD + S3I-201 and Das + S3I-201). Results also showed that xenograft tumors of Panc-1 
showed increased sensitivity to the concurrent treatment with the approved combination 
therapy, gemcitabine and erlotinib, similarly to the treatment with Das and S3I-201 (Fig. 
8B, gemcitabine + erlotinib compared with Das + S3I-201). Studies also showed that 
xenografts of Panc-1 were more sensitive to drug combinations than xenografts derived 
from Colo-357 cells (Fig. 8B, compare with Fig. 8A), which is consistent with the in vitro 
cell growth/viability and apoptosis data (Figs. 5 and 6D). Thus, significant differences (p 
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< 0.05) between the tumor volumes (sizes) for Colo-357 tumors in mice treated with the 
combination inhibitors and the control tumors occurred at day 20 and onward 
posttreatment, compared with the significant differences that occurred at day 10 
posttreatment between the tumor volumes for xenografts of Panc-1 that were treated 
with the combination of Das and S3I-201 or gemcitabine and erlotinib and the tumor 
volumes for control tumors (Fig. 8). The in vivo antitumor effects of the combination 
treatment with S3I-201 and Das or S3I-201 and ZD are consistent with the in vitro 
antitumor cell data and together indicate that aberrant Stat3 cooperates with 
hyperactive EGFR or Src to sustain human pancreatic cancer. There were no obvious 
signs of toxicity of any of the drugs or drug combinations, and the average weights of 
mice for control and treated mice were 23 to 26 mg at the end of the studies.  
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Figure 8: In vivo study of growth inhibiton of human pancreatic cancer xenografts 
Human pancreatic Colo-357 tumorbearing mice were given ZD (75 mg/kg i.v.), Das (15 mg/kg i.v.), and 
S3I-201 (5 mg/kg i.v.) alone or in combination every 2 or 3 days for the first 2 weeks and then daily for 5 
days each week for the next 3 weeks (A), or Panc-1 tumorbearing mice were given ZD (75 mg/kg i.v.), 
Das (15 mg/kg i.v.), and S3I-201 (5 mg/kg i.v.) alone or in combination every 2 or 3 days, or given 
erlotinib (5 mg/kg i.v., every day) in combination with gemcitabine (100 mg/kg i.v., every 3 days) for 48 
days (B). Tumor sizes, measured at 2- to 5-day intervals, were converted to tumor volumes and plotted 
against days. Values, mean and S.E.M. n= 7 or 8 mice per group. *, p <0.05; ***, p <0.001. 
  
Fig 8 
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Discussion 
Pancreatic cancer is a lethal disease that has remained a challenge to treatments. The 
lack of understanding of the disease has also limited the chances of designing effective 
therapeutic modalities. We present evidence from in vitro and in vivo studies that the 
multiple targeting of Stat3 and EGFR or Stat3 and Src has the potential to induce strong 
antitumor responses in pancreatic cancer. Our study shows that the concurrent 
treatment with the Stat3 inhibitor, S3I-201, and the EGFR inhibitor, ZD, or S3I-201 and 
the Src inhibitor, Das, induced an enhanced tumor growth inhibition, with reduced tumor 
sizes in xenograft models developed from the metastatic pancreatic cancer line, Colo-
357, and the epithelioid carcinoma line, Panc-1. The robust antitumor effects of the 
combination therapy contrast the weaker antitumor responses to the inhibition of EGFR, 
Src, or Stat3 alone in the xenografts of Colo-357 and Panc-1, suggesting the 
monotargeting of EGFR, Src, or Stat3 alone might not be sufficient to suppress the 
malignant phenotype and induce significant antitumor effects. These findings are 
generally consistent with the reports of dismal responses in molecular targeted 
monotherapy, such as the anti-EGFR monotherapy[34, 50].  Although the combined 
therapy of gemcitabine and the EGFR inhibitor, erlotinib, for locally advanced/metastatic 
pancreatic cancer[6, 51] may be justified by the same argument as the multiple-targeted 
therapy in our study, it is not without toxicities[34]. In our study, the treatment with Das 
and S3I-201 showed a similar antitumor efficacy. Given that the Das and S3I-201 
combination therapy is based on molecular targeting and is mechanism-based, this 
therapeutic modality presents advantages over the approved gemcitabine and erlotinib 
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combination. We also note from our in vitro study that the concurrent inhibition of Stat3 
and EGFR or Src promotes a higher sensitization of pancreatic cancer cells to 
gemcitabine than the inhibition of EGFR or Src alone. The present in vitro data also 
provide evidence that the combined inhibition of Stat3 and Src or EGFR induces 
stronger cell growth inhibition and apoptosis, mechanisms that would contribute to the 
decreased tumor growth in vivo. Molecularly, the enhanced antitumor effects of the 
concurrent inhibition of Stat3 and EGFR or Src against pancreatic cancer could in part 
be the result of the increased potential to down-regulate critical tumor-relevant genes. 
Altogether, the present study shows the in vivo efficacy of the concurrent targeting of 
aberrant Stat3 and EGFR or Src and provides support for the use of this multiple-
targeting modality as a therapeutic approach for pancreatic cancer.  
 
In vitro studies provide the biochemical and biological insights into the enhanced 
antitumor effects in vivo of the multiple targeting of Stat3 and EGFR or Src in pancreatic 
cancer. Our study provides strong evidence for a complex signaling cross-talk and a 
functional cooperation (Fig. 9), which would undercut the biological response of 
targeting only the EGFR, Src, or Stat3 protein. In the context of this signal integration 
(Fig. 9), data presented reveal a strong role for Src in increasing the aberrant EGFR 
activity in pancreatic cancer cells by promoting the phosphorylation of multiple tyrosine 
residues, including the Y1068EGFR and Y1086EGFR motifs. The induction of aberrant 
Stat3 activation is promoted by both hyperactive EGFR and Src activities. In this 
context, the induction of pY1068EGFR and pY1086EGFR by Src would serve to further 
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promote Stat3 activation, given that those two EGFR tyrosine motifs are essential sites 
for the binding and the activation of Stat3[22]. We also note that apart from the baseline, 
constitutive Stat3 activation in pancreatic cancer cells, which is caused primarily by 
EGFR and Src, there is a contributory role for Jak tyrosine kinases in the induction of 
Stat3 activation (Fig. 9). However, Jaks are unlikely to be the predominant mediators of 
the baseline, constitutive Stat3 activity, given that their inhibition by AG490 did not 
abolish aberrant Stat3 activation at the earliest time point, whereas the EGFR or Src 
inhibition completely attenuated the baseline, aberrant Stat3 activity. Instead, Jaks 
could provide a secondary, compensatory mechanism for Stat3 activation, as a part of a 
two-phase model for the induction of Stat3 activity in pancreatic cancer cells. A similar 
secondary induction of Stat3 activation via Jak activities has previously been observed 
in the head and neck squamous cell carcinoma line[49] and is suggested to be caused 
by the growth-stimulatory factors that are released from tumor cells[52] which in turn 
induce Jaks activity and thereby promote Stat3 activation. In this complex signaling 
structure (Fig. 9), the inhibition of EGFR or Src alone is unlikely to abolish the functional 
effects of abnormal Stat3 signaling. Instead, combining the direct inhibition of aberrant 
Stat3 with the EGFR or Src inhibition serves to provide the framework for substantially 
thwarting the oncogenic events with measureable beneficial outcome. Our data would 
suggest that the inhibition of Stat3 enhances the sensitivity of pancreatic cancer cells to 
the antitumor effects of ZD and Das.  
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Figure 9: A model of collabrative function of hyperactive EGFR, Src and Stat3 in support of human 
pancreatic cancer 
Hyperactive c-Src contributes to promoting the aberrant EGFR activation. Both hyperactive EGFR and 
Src induce constitutive Stat3 activation, whereas Jak activity contributes to promoting Stat3 signaling by 
serving as a compensatory mechanism. Aberrantly active Stat3 dysregulates the induction of target 
genes and, together with other potential mechanisms induced by the hyperactive EGFR and Src, induces 
cell growth, survival, and migration/ invasion, thereby promoting pancreatic tumorigenesis and 
progression.  
Fig 9 
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Additional in vitro biological data further indicate a collective role of EGFR, Src, and 
Stat3 in supporting pancreatic cancer. Although the inhibition of the activity of each of 
the three proteins induced some degree of antitumor cell response in vitro, albeit 
minimal, data are convincing that the simultaneous targeting of Stat3 and EGFR or Src 
has a higher potential to be more effective in inducing diverse antitumor cell effects 
against pancreatic cancer cells than the inhibition of EGFR or Src alone. The 
hyperactivation of EGFR signaling has been deemed a prognostic indicator of low 
survival among pancreatic cancer patients[53, 54]. In addition, there is evidence to 
indicate that the concurrence of hyperactive Src signaling potentiates the effects of 
aberrant EGFR[26]. Such increase of effect or the cooperation of activities and/or 
functions between the critical molecular entities that supports the pancreatic cancer 
phenotype can undermine the efficacy of a targeted monotherapy in pancreatic cancer. 
Indeed, the present data that the simultaneous inhibition of Stat3 and EGFR or Src 
induced greater antitumor cell effects and a higher sensitization to gemcitabine strongly 
supports this viewpoint. We infer from our study that the more robust tumor growth 
inhibition in vivo by simultaneous inhibition of Stat3 and EGFR or Src is the result of the 
concomitant suppression of the abnormal functions of both Stat3 and EGFR or Stat3 
and Src, suggesting that the concurrent targeting of Stat3 and EGFR or Stat3 and Src 
could be a more effective, multitargeted therapeutic modality for pancreatic cancer than 
the inhibition of EGFR, Src, or Stat3 alone.  
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A FUNCTIONAL NUCLEAR EPIDERMAL GROWTH FACTOR 
RECEPTOR, SRC AND STAT3 HETEROMERIC COMPLEX IN 
PANCREATIC CANCER CELLS 
 
Our study showed that Src regulated the activation of EGFR and both EGFR and Src 
regulated the activation of Stat3. However it is not known if the three proteins associate. 
A study of whether the proteins remain in a complex after activation, to exhibit a 
significant biological effect, would help understand the complex signaling mechanism in 
the pancreatic cancer cells. This study, thus aims to address intermolecular interaction 
between the three proteins. 
  
39 
 
Introduction 
Many intracellular biochemical processes are triggered by the assembly of proteins into 
macromolecular complexes. The association between proteins or of proteins with other 
molecular entities modulates protein conformation, providing a means to regulate the 
myriad of biochemical processes for the efficient management of vital biological 
responses. Moreover, protein dynamics and trafficking, and protein stability are also 
processes that can be modulated by the association of proteins with others. In the 
broader sense, inter-molecular associations allow specialty proteins, such as receptors, 
adapters, enzymes, and transcription factors to differentially modulate intracellular 
events, thereby creating the diversity in physiological responses and promoting context 
dependency. 
 
 During the induction of signal transduction, there is assembly of different proteins, each 
of which has specific functions important for the signal transduction and for the 
accompanying biological response. The traditional epidermal growth factor receptor 
(EGFR) signal transduction pathway incorporates the activation of the mitogen-activated 
protein kinase kinase (MEK)-mitogen-activated protein kinase/extracellular signal-
regulated kinase (ErkMAPK) and promotes mitogenic responses [55, 56]. Moreover, 
EGFR induction also promotes the activation of the Signal Transducer and Activator of 
Transcription (STAT) family of proteins, which similarly have a central role in EGF-
induced biological responses[56]. The STAT proteins are latent cytoplasmic 
transcription factors that are activated in response to cellular stimulation by cytokines 
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and growth factors[31] via the phosphorylation of a critical tyrosyl residue (Tyr705 for 
Stat3). The tyrosine phosphorylation of STATs is mediated by tyrosine kinases of 
growth factor receptors and by cytoplasmic tyrosine kinases, such as Src and Janus 
kinase (Jaks) families. Activated STATs as dimers in the nucleus bind to specific DNA 
response elements in the promoters of target genes to induce gene transcription. The 
nuclear translocation mechanism for STATs has been the subject of recent intense 
investigation. Stat3 nuclear translocation has been reported to be mediated by 
mechanisms, including the recognition and transport by importin-α and the Ran-GTPase 
[57], and the transport via chaperoning by MgcRacGAP[58], and by EGF receptor 
mediated endocytosis [59] and plasma membrane-associated lipid rafts trafficking 
mechanisms[60].  
 
The prevalence of many hyperactive signal transduction pathways that support the 
cancer phenotype is a major challenge to therapy. Further to the classical way of 
promoting crosstalks among multiple signaling pathways, macro-molecular protein 
assemblies provide additional unique mechanisms for inducing events that would 
support the malignant phenotype. Such a non-traditional signaling mechanism has been 
identified for the EGFR, which has been detected in the cell nucleus and observed to 
function as a transcription factor[61, 62]. Studies further revealed the nuclear EGFR 
complexes with Stat3 in breast cancer cells, and this complex induces specific genes, 
including the inducible nitric oxide synthase (iNOS) [63]. The additional EGFR function 
would compound its role as a mitogen and a promoter of cell survival, which all favor 
41 
 
cancer. In that regard, the concurrent aberrant activation of EGFR and downstream 
signal mediators, including Src and Stat3, which occur with high frequencies in human 
cancers reflects an overall signaling complexity that supports the cancer phenotype. For 
example, with reference to pancreatic cancer, aberrant activation of EGFR occurs in 30-
50% of cases[24], activated c-Src is noted in more than 70% of cases, and frequently 
accompanies EGFR overexpression[64], while aberrant Stat3 activation is also highly 
prevalent [27, 29, 32]. Importantly, our recent report that pancreatic cancer is more 
sensitive to the concurrent inhibition of aberrant Stat3 and EGFR or Src [65] show the 
dependence on multiple aberrant signaling pathways for the maintenance of the cancer 
phenotype and the responsiveness to therapy. To extend our earlier studies [65], we 
sought to probe the molecular and functional interplay between Stat3, EGFR and Src 
and the underlying mechanisms of support of the pancreatic cancer phenotype. We 
herein provide evidence for a functional nuclear heteromeric EGFR, Src and Stat3 
complex in pancreatic cancer cells, which promotes the induction of the c-Myc gene. 
During the revision of this paper, a study was reported on the detection of EGFR and 
Stat3 and EGFR and Src complexes following EGF stimulation of breast cancer 
cells[66], although our report is the first on the identification of a nuclear EGFR, Src and 
Stat3  heteromeric complex that promotes the c-Myc gene induction. Understanding the 
dynamics of the EGFR, Src and Stat3 molecular interactions in pancreatic cancer would 
provide basis to design novel effective multiple-targeted therapy approaches for 
pancreatic cancer. 
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Experimental Procedures 
Cells and Reagents. 
 The human pancreatic cancer, Panc-1 and Colo-357 lines have all been previously 
described [65, 67]. The immortalized human pancreatic duct epithelial cell (HPDEC) line 
was a kind gift of Dr. Tsao, OCI, UHN-PMH, Toronto)[38]. HPDEC were grown in 
Keratinocyte-SFM media supplemented with 0.2 ng EGF, 30 μg/mL bovine pituitary 
extract and containing antimycol. All other cells were grown in Dulbecco's modified 
Eagle's medium (DMEM) containing 5% iron-supplemented bovine calf serum and 100 
units/ml penicillinstreptomycin.  
 
Nuclear Extract Preparation and Gel Shift Assays.  
Nuclear extract preparation from cells was carried out as previously described [67].  
 
SDS-PAGE/Western Blot Analysis.  
Western blotting analysis was performed as previously described [35, 42] on whole-cell 
lysates, nuclear extracts, and on cytosolic and membrane fractions. Primary antibodies 
used are against pY845EGFR (Upstate Biotech, Millipore, Billerica, MA), pY705Stat3, 
Stat3, pY1068EGFR, pY1086EGFR, pY1173EGFR, EGFR, pY416Src, Src, and β-Actin 
(Cell Signaling Technology, Danvers, MA), and Tata-binding protein (TBP) (Santa Cruz 
Biotechnology, Santa Cruz, CA). 
 
Small-interfering RNA (siRNA) Transfection.  
siRNA sequences for EGFR and Src were ordered from Dharmacon RNAi 
Technologies, Thermo Scientific (Lafayette, CO). Sequences used are: EGFR sense 
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strand, 5′- GAAGGAAACUGAAUUCAAAUU-3′; EGFR antisense strand, 5′- 
pUUUGAAUUCAGUUUCCUUCUU-3′; control siRNA sense strand, 5′- 
AGUAAUACAACGGUAAAGAUU-3′; and control siRNA antisense strand, 5′- 
pUCUUUACCGUUGUAUUACUUU-3′. The c-Src SMARTpool siRNA reagent (NM- 
005417, Catalog # M-003175-01-05) was used for Src. Transfection into cells was 
performed using 20 nM of EGFR siRNA or 25 nM of Src siRNA and 8 μl Lipofectamine 
RNAiMAX (Invitrogen Corporation, Carlsbad, CA) in OPTI-MEM culture medium 
(GIBCO, Invitrogen Corporation). 
 
Immunostaining with laser-scanning confocal imaging.  
Details are provided in Supplementary Information, “Experimental Procedures”. 
Confocal analysis was performed by the examination of slides under Leica TCS SP5 
confocal microscope (Germany) at appropriate wavelengths. Images were captured and 
processed using the Leica TCS SP 5 software. Phenylarsine oxide was purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
Immunoprecipitation (IP), and Sequential Immunoprecipitation Studies. 
 Immunoprecipitation and sequential IP from whole-cell lysate or nuclear extracts and 
immunoblotting (250 μg total protein) were performed as previously described[44], using 
5 μL of anti-EGFR or anti-Src polyclonal antibody or the monoclonal anti-Stat3 antibody 
(Cell Signaling Technology). For the test of specificity, immunoblotting analysis using 
anti-EGFR, anti-Src and anti-Stat3 antibody was performed in the presence of the 
respective blocking peptide. For the sequential IP studies, nuclear extracts, prepared as 
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previously described[44], were subjected to similar Immunoprecipitation studies with 
regard to the first primary antibody by incubating with anti-EGFR antibody or IgG (for no 
antibody) (Santa Cruz) at 4°C overnight. The complexes were then collected with 20 μL 
protein A/G agarose beads (Santa Cruz), washed three times using wash buffer A 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, pH 8.0, 20 mM Tris-HCl, pH 8.0) and two 
times with wash buffer B (0.1% SDS, 1% Triton X-100, 2 mM EDTA, pH 8.0, 500 mM 
NaCl, 20 mM Tris-HCl, pH 8.0), and then eluted with freshly prepared elution buffer (1% 
SDS, 100 mM NaHCO3). The eluted complexes were then subjected to a second 
immunoprecipitation by incubating with anti-Src antibody or IgG (for no antibody) (Santa 
Cruz). The complexes were then precipitated, washed, eluted with lamelli buffer and 
then subjected to SDS-PAGE and Western blotting for Stat3. 
 
Chromatin Immunoprecipitation (ChIP) and Sequential ChIP Analyses. 
 For ChIP assay, cells in culture were treated with formaldehyde at a final concentration 
of 1%, for 10 min at room temperature followed by treatment with glycine at a final 
concentration of 0.125 M for 5 min at room temperature for cross-linking. Subsequently, 
cells were washed with ice-cold phosphate-buffered saline (PBS) and resuspended in 
and lysed with lysis buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM EGTA, 1 mM 
NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM dithiothreitol (DTT), 1X TLA, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 5% Nonidet P-40 [NP-40], and centrifuged. Then 
nuclear pellet was resuspended in nuclei lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 1% SDS and protease inhibitors) (Roche, Indianapolis, IN). The nuclear lysates 
were sonicated (Omni International, Kennesaw, GA) at 30% power for 3 pulses for 10 s 
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intervals on ice to shear DNA. The chromatin solution was pre-cleared with protein A/G 
agarose beads for 1 h at 4°C with rocking. Then the pre-cleared lysates were 
immunoprecipitated by incubating with anti-EGFR, anti-Src, or anti-Stat3 antibodies or 
with IgG (for no antibody) (Santa Cruz) at 4°C overnight with rocking. The complexes 
were collected with 20 μL protein A/G agarose beads (Santa Cruz), washed three times 
using wash buffer A (0.1% SDS, 1% Triton X-100, 2 mM EDTA, pH 8.0, 20 mM Tris-
HCl, pH 8.0) and two times with wash buffer B (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, pH 8.0, 500 mM NaCl, 20 mM Tris- HCl, pH 8.0). Then complexes were eluted 
with freshly prepared elution buffer (1% SDS, 100 mM NaHCO3). Cross-links were 
reversed by heating at 65°C in the presence of NaCl followed by proteinase K treatment 
(20 μl of a 20 mg/ml) for 6 h. The DNA was recovered and purified using DNA 
purification kit from Qiagen (Valencia, CA). The purified chromatin immunoprecipitated 
DNA was next used as a template for the polymerase chain reaction (PCR) 
amplification of the c-Myc promoter using the primers, Forward, 
5’AAAAGGGGAAAGAGGACCTGG-3’, and Reverse, 5’- 
TAAAAGGGGCAAGTGGAGAGC-3’ (Invitrogen). The 133 bp product was resolved on 
2% agarose gel. In the case of the sequential ChIP studies, the primary and the 
secondary immunoprecipitation followed the sequential IP studies described. The 
recovered complexes after the secondary immunoprecipitation were eluted with the 
elution buffer and then subjected to ChIP assay, as described. 
 
Preparation of anti-EGFR and mouse IgG1- GNP probes.  
Gold nanoparticles (GNPs), 0.1 nM, with a diameter of 40 nm were purchased from Ted 
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Pella Inc. (Redding, CA). Mouse monoclonal anti-EGFR [F4] antibody was purchased 
from Abcam (cat. no. ab62, conc. 1.2 mg/ml), and non-specific mouse monoclonal IgG1 
was purchased from Sigma (cat. no. M9629, conc. 1 mg/ml). Polyclonal anti-Stat3 
(conc. 0.2 mg/ml), polyclonal anti- Src (0.1 mg/ml), polyclonal anti-EGFR (0.2 mg/ml) 
and non-specific rabbit IgG (0.4 mg/ml) were purchased from Santa Cruz. All other 
chemicals and buffer ingredients for the assay development were purchased from 
Sigma. The anti-EGFR-GNP probe was prepared by adding 10 μl of mouse monoclonal 
anti-EGFR antibody to 1 ml of GNPs. After incubation for 15 min at room temperature, 
the probe was blocked with 2.5 mg BSA for 30 min. After the centrifugation at 10,000 
rpm for 5 min, the supernatant was discarded and the nanoparticle residue was 
redispersed in 0.5 ml of 0.25% BSA in 10 mM phosphate buffer (PB). The probe was 
then used in the assay. The negative control mouse IgG1-GNP probe was prepared by 
adding 10 μl of mouse monoclonal IgG1 antibody to 1 ml GNPs, and following the 
procedure identical to the one used for the EGFR probe preparation. Mouse IgG1 was 
used here to prepare the control probe, because the anti- EGFR monoclonal antibody is 
a mouse IgG1 type antibody. 
 
Detection and kinetic binding study of EGFR from nuclear extract to the GNP 
probes.  
The Panc-1 nuclear extract sample was diluted in phosphate buffer (PB) to 1 mg/ml of 
total protein. In a sample cell for Dynamic Light Scattering (DLS) measurement (Hellma 
cuvette QS 3 mm), 20 μl of the anti-EGFRGNP probe was mixed with 2 μl of the 
sample, and the particle size increase was read with a DLS instrument (Zetasizer Nano 
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ZS90 DLS system, Malvern Instruments Ltd, England) at exactly 1, 6, 11, 16, and 30 
min after the mixing. The same experiment was also performed using the mouse IgG1-
GNP probe. In order to confirm the specificity of the anti-EGFR-GNP probe in the 
detection of EGFR from nuclear extract, an inhibition experiment was conducted by 
treating 5 μl of the sample with 1 μl of monoclonal anti- EGFR antibody at room 
temperature for 7 min and 24 min prior to using the sample in the assay. After this 
incubation, 20 μl of the anti- EGFR-GNP probe was mixed with 2 μl of the treated 
sample, and the particle size was read at 1, 6 and 11 min after the mixing. 
 
Protein complex binding partner study using polyclonal antibody.  
In a 1.5 ml microcentrifuge tube, 80 μl of the anti-EGFRGNP probe was mixed with 8 μl 
of the sample. After incubation for 30 min at room temperature, this solution was divided 
into four 20 μl portions. After transferring into the sample cell, the particle size of each of 
these portions was read with a DLS instrument. After this reading, the solution was 
spiked with a polyclonal antibody: either with 1 μl of anti-Stat3 or 2 μl of anti-Src or 1 μl 
of anti- EGFR or 0.5 μl of rabbit IgG. The particle size increase was read at exactly 5 
min and 10 min after the start of the first reading. 
 
DLS measurements.  
The DLS measurements of all sample solutions were conducted using a Zetasizer Nano 
ZS90 DLS system equipped with a red (633 nm) laser and an Avalanche photodiode 
detector (APD) (quantum efficiency>50% at 633 nm) (Malvern Instruments Ltd). DTS 
applications 5.10 software was used to analyze the data. The average particle size (Z-
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average) of the solution was obtained using a Cumulant method. For each sample, ten 
DLS measurements were conducted with one run, and each run lasted for 10 seconds. 
All measurements were done at a 90° detection angle. 
 
Results 
Detection of EGFR, Src and Stat3 heterocomplex using coimmunoprecipitation 
and immunoblotting analysis.  
Our previous work[65, 68] and others[28, 29] showed that Stat3, EGFR and Src are 
constitutively-activated in human pancreatic cancer cells, including Panc-1 and Colo-
357 cells. We sought to probe the assembly of the three entities. In 
coimmunoprecipitation (co-IP) with immunoblotting analysis, EGFR immunecomplex 
from Panc-1 or Colo-357 whole-cell lysates contained both Src and Stat3 (Fig. 10A(i)), 
Src immunecomplex contained both EGFR and Stat3 (Fig. 10A(ii)), while Stat3 
immunoprecipitate contained EGFR and Src (Fig. 10A(iii)). To verify the specificity of 
the immunoreagents, nonspecific rabbit IgG was used to prepare immunoprecipitates 
and immunoblotted for Src, Stat3 or EGFR, each of which showed no detectable protein 
(Fig. 10A, IgG, and data not shown). Moreover, immunoblotting analysis performed on 
immune precipitates in the presence of the respective blocking peptides (BP) showed a 
complete or near complete block of the immune detection of Stat3, Src or EGFR, 
compared to the levels detected in the absence of the blocking peptides (Fig. 10A(iv)-
(vi), compare + BP, lower panels to – BP, upper panels). These results further 
demonstrate the specificity of the antibody-based detection in the present study.  We 
were interested in determining the effect of siRNA knockdown of EGFR or Src on the 
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complex formation. Coimmunoprecipitation with immunoblotting studies of whole-cell 
lysates of Panc-1 cells showed that when EGFR is knockdown by siRNA (Fig.10B(i) and 
(ii), upper band), Src immunecomplex remains associated with Stat3 (Fig. 10B(i), 
IP:Src), and vice-versa (Fig. 10B(ii), IP:Stat3). Likewise, when Src is knockdown by 
siRNA (Fig. 10B(iii) and (iv), upper band), EGFR immunecomplex remains associated 
with Stat3 (Fig. 10B(iii), IP:EGFR), and vice-versa (Fig. 10B(iv), IP:Stat3). Scrambled 
(con) siRNA has no effect. These findings together indicated EGFR, Src and Stat3 form 
a heteromeric complex in Panc-1 and Colo-357 cells, and that Stat3 remains associated 
with Src or EGFR, respectively, upon the siRNA knockdown of EGFR or Src.  
 
Given the reported nuclear EGFR and Stat3 complex in breast cancer cells [63], we 
asked the question whether the observed heteromeric complex was present in the 
nucleus. Nuclear extracts were prepared and subjected co-IP with immunoblotting 
analysis. Results show that EGFR immunecomplex contained both Stat3 and Src (Fig. 
10C(i), IP:EGFR), Src immunecomplex contained both Stat3 and EGFR (Fig. 10C(ii), 
IP:Src), while Stat3 immunecomplex contained both EGFR and Src (Fig. 10C(iii), 
IP:Stat3). These data demonstrated that the presence of the EGFR, Src and Stat3 
heteromeric complex in the nucleus. For studies of the specificity of the 
immunoreagents, the non-specific rabbit IgG pull-down samples were similarly 
immunoblotted and showed no detectable EGFR, Src or Stat3 (Fig. 10C, IgG and data 
not shown). The heteromeric complex was validated by performing sequential 
immunoprecipitation analysis, whereby EGFR immunecomplex (IP:EGFR) was further 
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subjected to a secondary Immunoprecipitation using anti-Src antibody 
((IP:EGFR/IP:Src) and then immunoblotted for EGFR and Stat3. The results of these 
studies showed the presence of EGFR and Stat3 in the sequential immunoprecipitates 
(Fig. 10C(iv), IP:EGFR/IP:Src). By contrast, IgG pull-down that was subjected 
immunoblotting for EGFR, Src or Stat3 showed no detectable levels (Fig. 10C(iv), IgG), 
further confirming the specificity of the immunoreagents used. Moreover, 
immunoblotting analysis probing for the Tata-binding protein (TBP) (Fig. 10C(vi)) 
confirmed the extracts used in these studies are of nuclear origin. 
 
Results so far show the EGFR, Src and Stat3 complex is detected in both whole-cell 
and nuclear lysates. We were therefore interested to determine the relative levels of 
EGFR, Src and Stat3 in the different sub-cellular fractions and to assess whether size of 
each of these proteins in the different sub-cellular locations. Membrane and cytosolic 
fractions, and nuclear extracts were prepared from Panc-1 cells according to 
established protocol using NP-40 lysis and low salt (100 mM NaCl) for cytosolic extract, 
high salt (400 mM NaCl) extraction for nuclear extracts, and 1% Triton X-100 buffer for 
membrane fraction. Samples of equal total protein were then subjected to SDS-PAGE 
and immunoblotting analysis. Immunoblotting analysis of sub-cellular fractions of equal 
total protein shows the size of EGFR, Src, or Stat3 obtained in the membrane or 
cytosolic fractions, or in nuclear extracts are the same (Fig. 10D). Results further show 
that the levels of total EGFR protein are highest in the membrane, and are higher in the 
cytosolic fraction than in the nuclear extract (Fig. 10D (i)). By contrast, results show that 
51 
 
Stat3 levels are highest in the cytosol fraction, and higher in the nuclear extract, 
compared to the levels associated with the cell membrane (Fig. 10D(ii)). The results for 
Src were also different and showed the membrane-associated levels were higher than 
the levels detected in the cytosolic fraction and nuclear extracts, which were nearly 
idetnifcal (Fig. 10D(iii)). These results together reveal for the first time the detection of c-
Src in the nucleus, together with the presence of EGFR and Stat3. 
 
In the stimulation of the EGFR signaling, key phospho-tyrosine (pY) peptide motifs of 
the receptor are induced, which recruit a variety of signaling proteins, including 
Stat3[22, 69]. The Stat3 protein, via its SH2 domain binds to the receptor, engaging in 
pY-SH2 domain interactions[70]. We therefore sought to define the observed nuclear 
assembly of the EGFR, Src and Stat3 complex by using the known Stat3-binding EGFR 
motifs, pY1068 peptide and pY1086 peptide, and the newly reported Stat3 peptide 
inhibitor, SPI, which is derived from the Stat3 SH2 domain and is capable to block the 
binding of the Stat3 SH2 domain to pY peptide motifs[71]. Nuclear extract preparations 
from Panc-1 cells were first incubated with or without peptides for 2 h at room 
temperature, subjected to immunoprecipitation analysis using anti-Stat3 antibody, and 
the Stat3 immunecomplex subjected to SDS-PAGE and immunoblotting analysis for 
EGFR and Src. Results showed no detectable EGFR protein in the Stat3 
immunecomplex from nuclear extracts pre-incubated with the three peptides (Fig. 
10E(i)), suggesting the EGFR-Stat3 interaction is facilitated by pY1068 and 
pY1086EGFR, and requires the key amino acid residues, 588-615[71] that make up the 
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Stat3 SH2 domain peptide inhibitor SPI. By contrast, similar incubation with the SPI 
peptide has minimal effect on the detectable Src protein associated with the Stat3 
immunecomplex, suggesting a direct interaction between Src and Stat3, which is 
independent of the amino acid residues 588-615 of the Stat3 SH2 domain, and the 
detection of such a complex in the nucleus. These findings together indicate that there 
is a key requirement for the Stat3 SH2 domain and the EGFR peptide motifs, pY1068 
and pY1086 in the assembly of the nuclear EGFR, Src and Stat3 complex. We further 
sought to determine the importance of EGFR or Src in the assembly of the nuclear 
complex by examining the effect of siRNA knockdown. Immunoblotting analysis of 
immunecomplexes of Stat3 (IP:Stat3), EGFR (IP:EGFR) or Src (IP:Src) prepared from 
nuclear extracts showed that the siRNA knockdown of Src (Fig. 1F(i), upper panel) has 
little effect on the association of Stat3 with EGFR in the nucleus (Fig. 1F(i), IP:Stat3, 
IP:EGFR), while similarly, the knockdown of EGFR (Fig. 1F(ii), upper panel) did not alter 
the binding of Stat3 with Src (Fig. 1F(ii), IP:Stat3, IP:Src). Scrambled (con) siRNA has 
no effect. These data parallel the findings of the whole-cell lysates analysis in Figure 
10B on the lack of effect of the knockdown of EGFR or Src on the association of Stat3 
with the remaining partner. These data indicate that the knockdown of one protein does 
not preclude the interaction between the other two protein partners.  
 
Given the results of the siRNA knockdown studies, we sought to determine if the 
heteromeric complex formation is dependent on the tyrosine kinase activities of EGFR 
and Src. Panc-1 cells were first treated with the selective EGFR inhibitor, Iressa 
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(ZD1839, ZD), the Src inhibitor, Dasatinib (Das), or the Stat3 dimerization disrupting 
inhibitor, S3I-201[21] prior to co-IP and immunoblotting analyses. Compared to IgG, 
immunoblotting of immunecomplex of EGFR showed no effect of treatment of cells for 1 
h with any of the inhibitors (Fig. 1G, IP:EGFR, lanes 3, 6, and 8, compared to lane 2). 
On the other hand, immunoblotting analysis of EGFR immunecomplex showed 
decreased levels of associated Stat3 protein, but not Src in cells treated with ZD, Das, 
or S3I-201 for 24 (Fig. 1G, lanes 4, 7, and 9). We surmise that both the EGFR and Src 
kinase activities promote the association of Stat3 with EGFR in the nuclear heteromeric 
complex, while the inhibition of EGFR or Src kinase alone does not preclude EGFR/Src 
interaction. Furthermore, a Stat3 dimerization disrupting inhibitor blocks Stat3 
association in the complex; however, the disruption of Stat3 dimerization, and hence its 
binding to EGFR does not preclude EGFR/Src interaction. The observation that the 
nuclear heteromeric EGFR, Src, and Stat3 complex was not completely dissociated and 
that EGFR/Src complex persisted by 24-h inhibition of EGFR (ZD) or Src (Das) (Fig. 1G, 
lanes 4, and 9) has important clinical implications in terms of the responsiveness of 
pancreatic cancer cells to a monotherapy targeting EGFR or Src. 
 
Several mechanisms have been reported for EGFR nuclear translocation, including 
receptor endocytosis, endosomal sorting machinery, importins alpha1/beta1, and 
exportin CRM1[72, 73]. Previous studies have shown that Stat3 nuclear translocation is 
facilitated by EGFR-mediated endocytosis[59]. However, the siRNA knockdown of 
EGFR did not affect the nuclear presence of Src/Stat3 (Fig. 10F(ii)), suggesting EGFR-
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mediated mechanisms may not be essential for the nuclear presence of Stat3 or Src. 
 To determine whether endocytosis is required for the nuclear presence of the 
heteromeric complex, cells were treated with the pharmacological inhibitor of 
endocytosis, phenylarsine oxide[59]. In contrast to PAO induced inhibition of nuclear 
Stat3 DNAbinding activity induced by EGF [59], immunoblotting analysis showed 
treatment with PAO has no effect on the nuclear presence of EGFR, Src and Stat3 
heterocomplex in pancreatic cancer cells (Fig. 10H), suggesting the nuclear presence of 
the heteromeric complex is not dependent on endocytosis. Altogether, these findings 
extend the previously reported nuclear EGFR and Stat3 complex in breast cancer 
cells[63]  by showing that EGFR, Src and Stat3 associate into a complex in a manner 
where all three proteins interact. However, our study does not exclude the possibility 
that other proteins could be present in the complex.  
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Figure 10: Co-immunoprecipitation analysis of EGFR, Src and Stat3 asscoiation in Panc-1 and 
Colo-357 cells 
(A) and (B), immunoblotting analyses of immunecomplexes of EGFR (IP:EGFR), Src (IP:Src), and Stat3 
(IP:Stat3), or of non-specific IgG non-immunoprecipitate prepared from whole-cell lysates of Panc-1 and 
Colo-357 cells untransfected (A) or of Panc-1 cells transfected with EGFR siRNA, Src siRNA, or control 
(con) siRNA (B) and probing for Src, Stat3 and EGFR in the presence or absence of Stat3 blocking 
peptide (Stat3 BP), Src blocking peptide (Src BP) or EGFR blocking peptide (EGFR BP); (C), 
immunoblotting analyses of immunecomplexes of EGFR (IP:EGFR), Src (IP:Src), Stat3 (IP:Stat3), or of 
non-specific IgG non-immuneprecpitate prepared from nuclear extracts of Panc-1 or Colo-357 cells and 
probing for Stat3, EGFR, Src, or the Tata-binding protein (TBP); (D), immunoblotting analysis of 
membrane (mem) and cytosolic (cyto) fractions and nuclear (nuc) extracts from Panc-1 cells probing for 
(i) EGFR, (ii) Stat3 and (iii) Src; (E), immunoblotting analyses of Stat3 immunecomplex (IP:Stat3) 
prepared from nuclear extracts pre-incubated for 2 h with 100 μM each of the peptides, pY1068, pY1086, 
or SPI; (F), and (G), immunoblotting analyses of immunecomplexes of EGFR (IP:EGFR), Src (IP:Src), 
Stat3 (IP:Stat3), or of non-specific IgG non-immunecomplex prepared from nuclear extracts of Panc-1 or 
Colo-357 cells untransfected (E) or transfected (F) and (G) with Src siRNA, EGFR siRNA, or control (con) 
siRNA, or treated with the EGFR inhibitor (ZD1839, ZD), Src inhibitor (Dasatinib, Das), or Stat3 inhibitor 
(S3I-201) for 1 or 24 h (G) and probing for EGFR, Src, Stat3; or (H) immunoblotting analysis of nuclear 
extracts prepared from Panc-1 cells treated or untreated with phenylarsine oxide (PAO) and probing for 
Src, Stat3, EGFR, and the Tata-binding protein (TBP); bands corresponding to proteins in gel are shown; 
input: except where indicated, represents the respective immunoprecipitated protein probed in the same 
amount of lysate or nuclear extract used in the assay; IP:EGFR/IP:Src, sequential immunoprecipitation 
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with anti-EGFR and then anti-Src antibody; M, molecular weight marker, of which 75kDa protein marker is 
shown; Data are representative of 3 independent studies. 
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Detection and Analysis through Nanoparticle Sizing (DANS) technology with 
Dynamic Light Scattering to detect EGFR, Src and Stat3 heterocomplex. 
 The EGFR, Src and Stat3 association was further probed using DANS (Detection and 
Analysis through Nanoparticle Sizing) technology[74-78]. The principle of DANS 
technology for protein complex detection and binding partner analysis is a single-step 
solution immunoassay based on gold nanoparticle (GNP) immunoprobes coupled with 
dynamic light scattering (DLS) detection. Details of this technology are provided as part 
of Supplemental Information, “Results”. Based on this general principle, the assay is 
designed to detect and identify protein binding partners of a protein complex. The 
kinetic binding assay revealed and confirmed that the anti- EGFR-GNP probe detects 
EGFR from the sample specifically (Fig. 11A(i)). The increase in particle size obtained 
with the anti-EGFRGNP probe was much larger than the one obtained with the non-
specific mouse IgG1 control probe (Fig. 11A(i)). The approximate net increase of the 
average nanoparticle size of the assay solution was about 70 nm, after deducting the 
size increase caused by nonspecific interactions. For the mouse IgG1- GNP probe, the 
particle size increase was less than 10 nm after incubation with the sample for 30 min. 
Furthermore, the steepness of the kinetic curve for the EGFR probe suggested specific 
interactions in the assay system, while the shallow curve for the mouse IgG1 probe 
indicated the small size increase of the nanoparticle probes was due to non-specific 
interactions. To further confirm the specificity of anti-EGFR-GNP probe in the detection 
of EGFR from nuclear extract, an inhibition experiment was conducted in which the 
extract was first treated with the monoclonal anti-EGFR antibody. It is expected that the 
binding between the monoclonal antibody and the EGFR protein from the sample will 
59 
 
block the subsequent binding of EGFR (in the sample) to the GNP immunoprobes, 
therefore, leading to decreased nanoparticle size increase during the kinetic assay. 
Indeed, data shown in Figure 11A(ii) confirmed the inhibition effect of the monoclonal 
anti-EGFR antibody. The magnitude of this inhibition was correlated to the sample 
treatment time: the 24-min treatment inhibited the particle size increase in the assay 
stronger than the 7 min- reatment (Fig. 11A(ii)).  
 
After using the anti-EGFR-GNP probe to “catch” the EGFR protein or protein complex 
from the nuclear extract sample, a second polyclonal antibody (anti-Stat3, anti-Src, 
anti8 EGFR antibodies, and non-specific rabbit polyclonal IgG) was then added to the 
assay solution to identify the binding partner of the complex. In negative control studies 
using the mouse IgG1-GNP probe, particle size remains nearly unchanged after the 
addition of the four polyclonal antibodies (Fig. 11B(i)). This result confirmed the kinetic 
binding study that the non-specific mouse IgG1-GNP probe did not bind with the EGFR 
protein or protein complex from the sample. The addition of a polyclonal antibody itself 
to the assay solution did not cause significant nanoparticle size change. 
 
 By contrast, with the anti-EGFR-GNP probe, significant particle size increase was 
observed when anti-Stat3 or anti-Src antibody was added to the assay solution (Fig. 
11B(ii), anti- Stat3, Src). A smaller size increase was observed from anti-EGFR 
antibody (Fig. 11B(ii), anti-EGFR) and the rabbit IgG (Fig. 11B(ii), IgG). Per the assay 
principle (see Fig. S1 in Supplemental Information, “Results”), the substantial particle 
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size increases observed from the addition of anti-Stat3 or anti-Src antibody to the assay 
solution can only explained by the presence of EGFR in complex with Stat3 and Src in 
the nuclear extract. EGFR was specifically bound to the nanoparticle immunoprobes, 
bringing along the Stat3 and Src proteins to the nanoparticle surface, and the 
subsequent incubation of this assay solution with anti-Stat3 or anti-Src antibody led to 
further increase of the nanoparticle size. Furthermore, it appears that there is an equal 
amount of Stat3 and Src proteins in the EGFR, Src, and Stat3 complex. In multiple 
assays conducted so far, the size increase caused by anti-Src antibody is always just 
slightly lower than the case of anti-Stat3 antibody. Src is a smaller protein (60 KDa) than 
Stat3 (80-90 KDa). Therefore, with the binding of the same amount of antibody to the 
protein complex-GNP conjugates, the particle size should be just slightly smaller in the 
case of anti-Src assay solution than anti-Stat3 assay solution.  
 
Compared anti-Stat3 or anti-Src antibody, the particle size increase upon addition of 
anti- EGFR antibody to the assay solution is much smaller, only slightly higher than the 
nonspecific rabbit IgG. This is explained by the fact that Stat3 and Src are located on 
the surface of the nanoparticle-bound EGFR protein, therefore, block the binding of anti- 
EGFR antibody to the bound EGFR proteins. The effectiveness of polyclonal anti-EGFR 
antibody with the EGFR protein in the sample was confirmed in a different experiment 
(data not shown). This result indirectly suggested that the EGFR protein detected by the 
nanoparticle immunoprobe from the nuclear extract exists as a complex with Stat3 and 
Src protein. 
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Figure 11: Studies of protein complex and protein binding partners using the Detection and 
Analysis through Nanoparticle Sizing technology 
(A) Kinetic binding assay of EGFR-gold nanoparticle (GNP) probe (or mouse IgG1-GNP probe as 
negative control) binding to (i) EGFR protein and its complex from Panc-1 nuclear extracts, and the (ii) 
inhibitory effect of the mouse monoclonal anti-EGFR antibody on the EGFR-GNP probe binding to the 
EGFR protein; and (B) Protein complex binding partner analysis whereby the polyclonal anti-Stat3, anti-
Src or anti-EGFR antibody or the non-specific rabbit IgG (negative control) is added to the assay solution 
prepared from the (i) non-specific mouse IgG1-GNP probe (negative control), or (ii) anti-EGFR-GNP 
probe; Data are representative of 4 independent studies. 
  
Fig.11 
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Detection of EGFR, Src and Stat3 heterocomplex by Immunofluorescence with 
laser-scanning confocal microscopy.  
Immunofluorescence with laser-scanning confocal microscopy allowed visualization of 
the intracellular distribution and localization patterns of EGFR, Src and Stat3. 
Immunofluorescence with laser-scanning confocal microscopy confirmed the 
localization patterns and showed that in contrast to the negative staining (Fig. 12B(i), 
left panel), EGFR appearance is punctuate (red) at the plasma membrane, and in the 
cytoplasm and the nucleus (Fig. 12B(i), single). Similar localizations for Src (blue) and 
Stat3 (green) were observed, but with greater presence in the nucleus (Fig. 12B(i), 
single). There are stainings for colocalization of EGFR and Src (magenta, see arrows), 
EGFR and Stat3 (yellow, see arrows), Src and Stat3 (cyan, see arrows), and of all three 
entities (pale yellow/white, see white arrows) at the plasma membrane, cytoplasm, 
perinuclear and nuclear spaces (Fig. 12B(i), merge). These studies confirm previous 
reports of the association of EGFR and Stat3 in similar intracellular spaces[59, 63]. 
Importantly, the data show for the first time the presence of a heteromeric EGFR, Src 
and Stat3 complex in the nucleus, as observed by the co-IP and immunoblotting 
analyses, and confirmed by DANS/DLS analysis (Figures 10 and 11). These data 
contrast the results observed for the normal human pancreatic duct epithelial cells 
(HPDEC) (Fig. 12A). Immunofluorescence staining with laser scanning confocal 
microscopy analysis of HPDEC shows a homogeneous distribution of EGFR (red), Src 
(blue) and Stat3 (green), all of which are strongly outside of the nucleus, with little 
evidence of co-localization (Fig. 12A).  
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Visualization of the intracellular distribution patterns of EGFR, Src and Stat3 upon 
inhibition of EGFR or Src tyrosine kinase by immunofluorescence with laser-scanning 
confocal microscopy indicated that as with the co-IP studies (Fig. 12E, the inhibition of 
Src or EGFR tyrosine kinase activity alone did not completely eliminate complex 
formation. However, Src or EGFR inhibition disrupted the localization patterns. Data 
shows EGFR, Src and Stat3 distribution in the cytoplasm and the nucleus following 1- or 
24-h treatment with EGFR or Src inhibitor (Fig. 12B(ii) and (iii), 1 h, and 24 h, single). 
Nuclear EGFR levels are diminished, but not abolished (Fig. 12B(ii), single). Thus, 
EGFR, Src and Stat3 remain localized in the nucleus following tyrosine kinase inhibition. 
Results further showed persistent EGFR and Src (magenta), and Src and Stat3 (cyan) 
associations in both the nucleus and cytoplasm following treatment for 1 h with EGFR or 
Src inhibitor (Fig. 12B(ii) and (iii), 1 h), similar to the data in Figure 12E (1 h). 
Furthermore, a nuclear EGFR and Stat3 association (yellow) is detected upon 24-h 
treatment with the EGFR inhibitor (Fig. 12B(ii), 100 nM ZD, 24 h), while nuclear 
associations of EGFR and Src (magenta), and of Src and Stat3 (cyan) are detected 
following treatment with Src inhibitor for 24 h (Fig. 12B(iii), 100 nM Das, 24 h). The 
moderate differences in the observed patterns of complex formation between the co-IP 
(Fig. 10E) and confocal data may be due to the sensitivity differences between the two 
approaches. Overall, the findings are consistent with the co-IP data (Fig. 10E) in 
showing that the inhibition of the kinase activity of EGFR or Src alone is insufficient to 
completely disrupt all the proteins from the complex. 
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Figure 12: Immunofluorescence with laser scanning confocal microscopy of EGFR, Src and Stat3 
association in Panc-1 Cells 
Cultured normal human pancreatic duct epithelial cells (HPDEC) (A) or pancreatic cancer, Panc-1 cells 
(B) were fixed, stained with primary antibodies against EGFR, Src and Stat3 and their corresponding 
secondary antibodies, ALexaFLuor405 (goat anti-mouse, EGFR, red), AlexaFluor488 (donkey anti-rabbit, 
Src, blue) and AlexaFluor546(goat anti-rat, Stat3, green) and analyzed by laser-scanning confocal 
microscopy for localization (single) and colocalization (merge) studies of EGFR (red), Src (blue) and Stat3 
(green) and the effects of treatment (i) without or (ii) with ZD1839 (ZD) or (iii) Dasatinib (Das) for the 
indicated times. Confocal images were collected using Leica TCS SP5 microscopes; Cyan, magenta, 
yellow and white/pale yellow arrows denote merged colors; single, one color capture, merged, three-color 
capture. Data are representative of 3 independent studies. 
  
Fig.12 
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EGFR, Src and Stat3 heteromeric complex regulates gene expression. 
 Previous report identified the presence of a nuclear EGFR and Stat3 complex in breast 
cancer cells, which showed that EGFR/Stat3 complex induces specific genes, including 
inducible nitric oxide synthase (iNOS)[59, 63]. It is therefore reasonable to propose that 
the nuclear EGFR, Src and Stat3 observed in the present study in pancreatic cancer 
lines could be responsible for the induction of a set of genes. In our previous work, we 
showed that the expression of c-Myc was refractory to the inhibition of EGFR, Src or 
Stat3 alone and that the concurrent inhibition of aberrant Stat3 activity together with 
EGFR or Src inhibition strongly suppressed c-Myc expression [65], suggesting the 
regulatory mechanisms promoting cancer supporting genes, such as c-Myc are rather 
complex. Thus, studies were performed to assess the functional significance of the 
heteromeric complex and we focused on the c- Myc gene. We pursued a chromatin 
immunoprecipitation (ChIP) analysis to determine whether c-Myc promoter is associated 
with the heteromeric complex. PCR amplification of DNA fragment using a primer 
against the c-Myc gene promoter and agarose gel electrophoresis showed that each of 
the anti- EGFR, Src, or Stat3 antibody-chromatin DNA immunoprecipitate contained the 
c-Myc gene (Fig. 13A(i), EGFR, Src and Stat3). To further confirm this finding, we 
pursued a modified sequential Immunoprecipitation similar to the one performed in Fig. 
11C(iv) in the context of a ChIP assay. The sequential ChIP assay in which EGFR 
chromatin immunecomplex was subjected to a second immunoprecipitation using anti-
Src antibody and similarly analyzed by PCR amplification and agarose gel 
electophoresis similarly detected the presence of the c-Myc gene (Fig. 13B(ii), 
EGFR/Src). 
66 
 
 
 To verify the specificity of the immunoreagents, the non-specific IgG was similarly used 
in ChIP assay, and the IgG immunoprecipitate, similarly analyzed by PCR for the c-Myc 
gene, showed no detectable levels (Fig. 13A, IgG). Taken together with the sequential 
immunoprecipitation data in Figure 10C(iv), these studies demonstrate that EGFR, Src 
and Stat3 form a detectable heterocomplex in pancreatic cancer cells that is associated 
with the expression of c-Myc. These findings support the complex regulation of genes in 
a manner that would confer a reduced sensitivity to the inhibition of EGFR, Src or Stat3 
alone. In that context, immunoblotting analysis of whole-cell lysates showed a degree of 
suppression, but not an elimination of the c- Myc gene in response to EGFR or Src 
knockdown alone (Fig. 13B), consistent with our previously published study[65]. 
Similarly, immunoblotting analyses further show no observable changes in the Cyclin 
D1 expression by the EGFR or Src knockdown (Fig. 13B), a decrease in iNOS 
expression by the knockdown of EGFR, but not Src, and a decreased expression of 
VEGF in response to the knockdown of Src, but not EGFR (Fig. 13B). Given that none 
of the genes studied here showed a consistent pattern of regulation by any one of 
EGFR or Src, we surmise they could be under the complex regulation by mechanisms 
involving the EGFR, Src and Stat3 heteromeric complex. To further investigate the 
relevance of the EGFR, Src and Stat3 complex in the regulation of c-Myc, we pursued a 
more extensive analysis of its expression in response to modulation of EGFR, Src and 
Stat3. Immunoblotting analysis showed that by contrast to siRNA knockdown of EGFR 
or Src alone, or the pharmacological inhibition of only Src or aberrant Stat3 activity, 
67 
 
which only moderately suppresses c-Myc expression, the concurrent knockdown of 
EGFR with Stat3 inhibition by S3I-201[21] or knockdown of Src with Stat3 inhibition, or 
the EGFR knockdown with Src inhibition (by Das) results in strong suppression of c-Myc 
expression (Fig. 13C(ii)). Bands corresponding to levels of expression were quantified, 
analyzed by ImageQuant, and the expression levels are represented as percent of 
control (in parenthesis). Results show over 73% suppression of c-Myc expression (Fig. 
13C(ii) following the concurrent modulation of any two of EGFR, Src and Stat3. 
Together, these studies indicate that the c-Myc gene is more responsive to the 
concurrent modulation of any two of the EGFR, Src and Stat3 proteins. The moderate 
change in the c-Myc expression in response to the concurrent transfection with EGFR 
siRNA and c-Src siRNA could be due to the fact that we could achieve only partial 
knockdown of Src (Fig. 13C(i)), although EGFR is significantly suppressed by the EGFR 
siRNA (Fig. 13C(i)), compared to the use of the pharmacological inhibitor, Das, which 
would strongly suppress Src activity. 
. 
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Figure 13: Chromatin Immunoprecipitation assay and Western blotting analysis of c-Myc, iNOS, 
Cyclin D1 and VEGF expression in Panc-1 and Colo-357 cells 
(A), Agarose gel electrophoresis of Polymerase Chain Reaction (PCR)-amplified c-Myc gene fragment 
from the chromatin DNA precipitated with antibody against EGFR, Src, Stat3, or with the non-specific IgG; 
and (B) and (C), Immunoblotting analysis of whole-cell lysates probing for EGFR or Src (B(i) and C(i)) or 
c-Myc, iNOS, Cyclin D1 or VEGF (B(ii) and C(ii)), and the effects of siRNA knockdown of EGFR (EGFR 
Fig. 13 
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siRNA), Src (Src siRNA) or control (con) siRNA, or S3I-201 or Das); bands corresponding to proteins or c-
Myc gene in gel are shown; M, molecular weight marker, EGFR/Src, sequential immunoprecipitation with 
anti-EGFR and then anti-Src antibody; Data are representative of 3 independent studies. 
 
Discussion 
Aberrations in the EGFR, c-Src and Stat3 signaling pathways occur with a high 
frequency in many human cancers[29, 32, 33, 79-81] and are associated with poor 
prognosis. Thus, there is increasing effort to gain further understanding of the role of 
these aberrant pathways in human tumors in order to derive novel, more effective 
treatment modalities. We present evidence for a nuclear EGFR, Src and Stat3 
heteromeric complex. The presence of the nuclear EGFR, Src and Stat3 complex was 
identified using a variety of approaches, including co-immunoprecipitation (co-IP) with 
immunoblotting analysis, sequential co- IP analysis, Detection and Analysis through 
(Gold) Nanoparticle Sizing with Dynamic Light Scattering, and by Immunofluorescence 
with laser-scanning confocal microscopy. In contrast to pancreatic cancer lines, normal 
human pancreatic duct epithelial cells did not show any evidence of EGFR, Src and 
Stat3 heteromeric complex formation, placing importance to the presence of the 
complex in the nucleus of cancer cells.  
 
De-regulation of gene expression is one of the hallmarks of cancer and is promoted by 
multiple mechanisms. It is well established that aberrant Stat3 activity promotes 
dysregulation of gene expression, and although a set of Stat3-responsive genes have 
been identified, there could still be others that are yet to be discovered. The exact 
mechanisms of how Stat3 would promote the expression of genes in the context of 
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supporting the malignant phenotype are not fully understood. Recent evidence of a 
nuclear EGFR pathway[61, 62] in which nuclear EGFR associates with Stat3, forming a 
transcriptionally-active EGFR/Stat3 complex that promotes the induction of iNOS in 
breast cancer cells [63] is evidence of how complex the Stat3-mediated regulation of 
gene expression could be in cancer cells. Other reports have shown a cooperation 
between Stat3 and NF-κB[82, 83] in promoting the transcription of genes. In that 
context, the present evidence extends our earlier report [65] in showing that the 
heteromeric EGFR, Src and Stat3 complex is associated with the induction of the c-Myc 
gene. There is likely to be other genes promoted by the EGFR, Src and Stat3 nuclear 
complex, and iNOS, VEGF, and Cyclin D1, which have been identified as induced by 
the EGFR/Stat3 complex or as Stat3-regulated genes[63, 84, 85] may be candidates for 
the regulation by the EGFR, Src and Stat3 complex. Taken together, these studies 
provide novel mechanistic insight into the de-regulation of gene expression that is a 
feature of cancer cells. The observation that the EGFR, Src and Stat3 complex is also 
detected in the cytoplasm raises the possibility it is formed extra-nuclear and 
transported into the nuclear space. However, it does not preclude the complex being 
assembled de novo in the nucleus. For Stat3, several nuclear translocation mechanisms 
have been proposed, including EGFR-mediated endocytosis [59, 73].However, the data 
that nuclear Src and Stat3 complex remain detectable under the conditions of EGFR 
knockdown, or when cells are treated with the general endocytosis inhibitor, 
phenylarsine oxide, suggests potential other nuclear translocation mechanisms could be 
involved. It has also been previously reported that EGFR has inherent nuclear 
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localization mechanisms, including endosomal sorting machinery, and interaction with 
importins α1/β1 [59, 73]. Other reported Stat3 nuclear translocation mechanisms 
include the Ran- GTPase [57], Sec61 translocon [86], and chaperoning by MgcRacGAP 
[58]. While we exclude endocytosis, any combination of these other mechanisms could 
facilitate the nuclear transport of the complex. Present data also suggest that only a 
portion of the levels of EGFR, Src and Stat3 are utilized in the formation of the nuclear 
complex, raising the possibility that there may be diverse cellular pools of EGFR, Src, or 
Stat3 with different accessibility limitations. There also could be different pools of pre-
associated complexes of the three proteins, a possibility that will be consistent with the 
report that cytoplasmic Stat3 exists as complexes with accessory scaffolding proteins 
[87]. Such pre-formed complexes would not only facilitate the signal induction[88], but 
may also serve to stabilize proteins.  
 
The incidence of signaling cross-talk has long been known, and the associations of 
EGFR with Src [89], Src with Stat3 [42, 90], and EGFR with Stat3 [22, 69] at the plasma 
membrane and perinuclear space [59] have all been reported. Specifically, Stat3 binds 
to pY1068 and pY1086 motifs of EGFR [22, 69], while Src binds to Y845EGFR. In 
cancer cells, aberrant Stat3 activation is promoted by hyperactive protein tyrosine 
kinases, including EGFR and Src [32, 33, 80], and evidence has indicated the 
phosphorylation of Y845EGFR, Y1068EGFR, and Y845EGFR motifs by c-Src in 
pancreatic cancer cells[22, 26, 65]. Data presented show the pY1068EGFR and 
pY1086EGFR motifs, and the Stat3 SH2 domain, specifically residues 588-615 are 
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essential for EGFR-Stat3 interaction within the EGFR, Src and Stat3 complex in 
nucleus. During the revision of this paper, a study was reported on the detection of 
EGFR/Stat3 and EGFR/Src complexes induced in breast cancer cells response to 
stimulation by EGF[66], While that study raises the potential that EGFR, Src and Stat3 
could assemble into a heteromeric complex, our study is the first to report on the 
presence of Src in the nucleus and on the identification of a nuclear EGFR, Src and 
Stat3 heteromeric complex that promotes c-Myc gene induction. It is not yet determined 
the exact configuration of the heteromeric complex. Additionally, the present evidence 
does not exclude the possibility that other accessory proteins could be present in the 
complex together with EGFR, Src and Stat3.  
 
Our more recent studies indicated a cooperation between EGFR, Src and Stat3 
functions for promoting and supporting the pancreatic cancer phenotype[65], and that 
the expression of c-Myc was refractory to the inhibition of EGFR, Src or Stat3 alone. 
The latter events failed to induce significant antitumor cell effects. The present finding 
that the blockade of EGFR or Src tyrosine kinase alone or the siRNA knockdown of 
either protein is insufficient to completely disrupt the entire complex formation might in 
part explain the limited effect of the modulation of any one of the three proteins on the 
pancreatic cancer cell phenotype, while the cancer cells are rather more sensitive to the 
concurrent inhibition of EGFR and Stat3 or of Src and Stat3 [65] which parallels the 
present observation that the concurrent modulation strongly represses c-Myc 
expression. Altogether, our study extends the present understanding of the molecular 
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events mediated by EGFR, Src and Stat3 [22, 26, 81] in showing that their relationship 
goes farther than signal transduction. More significantly, evidence that nuclear EGFR 
serves as a prognostic indicator in breast and ovarian cancers[91, 92], raises the 
possibility that nuclear EGFR, Src and Stat3 complex could be a predictor of patient 
response to therapy and the overall patient survival. 
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ROLE OF SRC IN PANCREATIC CANCER MIGRATION, INVASION AND 
METASTASIS 
 
Src is known to play a role in various tumor processes. However, our study indicates 
that Src plays a more significant role in pancreatic cell migration and invasion. The 
study here aims to understand the Src mediated regulation of cytoskeletal 
rearrangements and how they facilitate metastasis. A better understanding of the 
regulation would facilitate the development of effective therapeutic approach to reduce 
pancreatic cancer metastasis and hence the high mortality rate. 
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Introduction 
Pancreatic cancer is one of the most malignant tumors. Its poor prognosis is owing to its 
aggressive and high metastatic potential and there are no effective therapeutic 
approaches. Aberrant Src signaling is prevalent in many human cancers, with the 
existing evidence suggesting numerous roles for Src including cell proliferation, survival, 
angiogenesis, adhesion, invasion and metastasis [93]. Thus, Src has emerged as 
potentially important target for novel molecular-targeted anticancer drug design. 
However, while the initial evidence raises the potential that treatments that target Src 
activity might be useful as new therapeutics, the exact molecular mechanisms by which 
Src might support the pancreatic cancer phenotype are not fully defined. Moreover, 
recent studies from our lab showed that the inhibition of Src alone by Dasatinib had only 
a moderate effect on pancreatic cancer cell proliferation and survival [65]. Thus 
understanding how Src promotes pancreatic cancer cell migration and invasion and 
thereby contributes to pancreatic cancer metastasis would provide basis for developing 
approach for treating pancreatic cancer. 
 
There is some evidence that Src might regulate the invasion and migration in part 
through the induction of cytoskeletal rearrangements, although there is a little 
understanding of the molecular details. The activation of Src can be induced in 
response to the stimulation of various growth factor receptors, Integrins, or by 
stress[94]. In general the induction of Integrin signaling promotes focal adhesion kinase 
(FAK) autophosphorylation at Y397 and its aggregation at the focal adhesion site. The 
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activated FAK associates with Src, which further activates the two proteins. The 
complex of the two proteins further phosphorylates proteins downstream in the signaling 
pathways, including paxillin and p130Cas. On phosphorylation, p130CAS recruits Crk 
and DOCK180, which coordinate small GTPase activity required for cell migration and 
invasion [95, 96].  
 
The localization of Src is also an important event that is required for its function, and the 
ability of Src to promote malignant transformation is dependent on its intracellular 
localization. Although evidence shows that Src can be distributed to the plasma 
membrane, adhesion plaques, cell-cell contact and perinuclear membranes[96], its 
presence at the plasma membrane is associated with transforming activity. Apart from 
phosphorylating the downstream proteins, Src also alters the cellular localization of 
certain downstream proteins such as β-catenin and p120catenin. Src is known to 
increase the cytoplasmic retention of β-catenin and increase the membrane localization 
of p120catenin. 
 
During invasion, matrix metalloproteinases (MMPs) are localized to the membrane at 
the podosomes,  membrane extensions to the extracellular matrix (ECM), allowing the 
accumulated, activated MMPs to actively degrade ECM fibres. Src kinases induce 
podosome formation and promote proteolytic degradation of ECM proteins [97], 
suggests Src plays a role in cell invasion. 
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Our previous studies showing the inhibition of Src reduced the migration and invasion in 
pancreatic cancer further suggest Src is important in pancreatic cancer metastasis. 
However the exact mechanism of how Src regulates the cytoskeletal rearrangement in 
pancreatic cancer cells, thereby promoting cancer metastasis is not well defined. A 
study delineating the molecular mechanism of the Src-mediated regulation and 
induction of cytoskeletal rearrangements would provide a better insight into developing 
a better therapy to reduce pancreatic cancer metastasis.  
 
Experimental Procedures 
Cells and Reagents. 
 The human pancreatic cancer, Panc-1 and Colo-357 lines have all been previously 
described ([65, 67].  
 
Wound healing assay for migration. 
 Wounds were made using pipette tips in monolayer cultures of cells in 6-well plates. 
Cells were treated with or without increasing 100 nM Dasatinib and allowed to migrate 
into the denuded area over a 24-h period. The migration of cells was visualized at a 10x 
magnification using an Axiovert 200 Inverted Fluorescence Microscope (Zeiss, 
Gottingen, Germany), with pictures taken using a mounted Canon Powershot A640 
digital camera[98] (Canon USA, Lake Success, NY). Distance migrated by the cells into 
the denuded area were quantified. 
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SDS-PAGE/Western Blot Analysis. 
 Western blotting analysis was performed as previously described[35, 42]. Primary 
antibodies used are against pY566/567FAK, FAK, pY410p130Cas, pY418Paxillin, 
Paxillin, pY421Cortactin, Cortactin (Cell Signaling Technology, Danvers, MA), and 
p130Cas (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
Immunoprecipitation (IP) Studies. 
 Immunoprecipitation from whole-cell lysates and immunoblotting analysis (250 μg total 
protein) were performed as previously described [44],using anti-Src monoclonal 
antibody (Santa Cruz, CA). 
 
Results 
Inhibition of Src reduces cell migration. 
 Wound healing assay was done to measure the effect of Src inhibition on cell migration 
in pancreatic cancer cells. Migration of Panc-1 cells was observed to be lower in cells 
treated with 100 nM Dasatinib following 24h treatment (Fig 14a and 14b.) suggesting 
the inhibition of Src reduced the cell migration. 
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Figure 14: Inhibition of Src reduces cell migration in pancreatic cacner cell line, 
Panc-1 in culture were wounded and treated with or without 100 nM Dasatinib for 24 h (11a. iv) and 
allowed to migrate into the denuded area in a wound healing assay. Cultures were visualized at 10x  
magnification by light microscopy (a) cultures were photographed  and (b) distance migrated by the cells 
into the denuded area was measured and plotted Values are the mean and SD of 6 independent 
determinations, data are representative of 6 independent studies. 
 
Inhibition of Src reduced the activation of FAK, p130Cas, paxillin, cortactin.   
Src is known to phosphorylate proteins at adhesion sites and to facilitate cytoskeletal 
rearrangement, thereby contributing to cell migration. Immunoblotting assay was done 
to measure the phosphorylation of FAK, p130Cas, paxillin, cortactin. The levels of 
phosphorylated FAK, p130Cas, paxillin and cortactin were reduced in cells treated with 
100 nM Dasatinib in Colo-357 (Fig 15a. Lane 2) and Panc-1 (Fig 15a. Lane 4) as 
compared to the untreated samples (Fig 15a. Lane 1 and 3). To further examine the role 
of Src in the regulation of key mediators of cytoskeletal rearrangement, Co-
immunoprecipitation studies were performed. Immunoblotting analysis showed Src 
associates with paxillin and cortactin (Fig 15(b)) (Lanes 1 and 3). The inhibition of Src 
Fig. 14 
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activity disrupted the complex between Src and paxillin and between Src and Cortactin 
in Colo-357 cells (Fig 15b. Lane 2) and Panc-1(Fig 15b. Lane 4). 
 
 
 
Figure 15: Effect of inhibition of Src on activation of FAK, p130 Cas, paxillin, cortactin 
(a) SDS-PAGE and Western blotting analysis of whole-cell lysates of equal total protein prepared from 
dasatinib treated or untreated Panc-1 cells probing for pY566/567FAK, FAK, pY410p130Cas, p130Cas, 
pY418paxillin, paxillin, pY421cortactin, cortactin (b)  Immunoblotting analyses of Src immunecomplexes 
(IP:Src) prepared from whole cell lysates of Colo-357 or Panc-1 cells treated with Src inhibitor dasatinib 
(Das), 24 h (Lanes 2 and 4) and probing for paxillin and cortactin.  
 
Discussion 
Existing reports have implicated Src in cell migration and invasion. Studies further show 
Src phosphorylates the downstream effectors at the adhesion site and forms complexes 
with the phosphorylated downstream proteins. These events contribute to promoting 
various cytoskeletal rearrangements. Our study shows that the inhibition of Src in 
Fig. 15 
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pancreatic cancer cells reduced the activated levels of FAK, p130Cas, paxillin and 
cortactin, and disrupted the complex between Src and paxillin and Src and cortactin. A 
further study of the effect that ensues after the activation of the effectors remain to be 
studied. Also a study of localization of these proteins at the focal adhesion site, would 
provide a better understanding of regulation of cell migration by Src. 
 
Furthermore our study provides evidence that Src supports the migration of pancreatic 
cancer cells invitro. Altogether, our findings suggest Src activity is a critical mediator of 
the induction of paxillin, cortactin, FAK and p130Cas, as part of the mechanism 
promoting pancreatic cancer cell migration. 
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GENERAL CONCLUSION AND DISCUSSION 
Cancer is characterized by multiple molecular aberrations, which support the malignant 
phenotype and moreover control the response to therapy. Accordingly, emerging 
evidence suggests targeting a single signal transduction molecule may not be sufficient 
to control cancer. By contrast, increasing evidence provides support for multiple-
targeting of signaling molecules as a potentially more effective approach for treating 
cancer. The EGFR, Src and Stat3 proteins are concurrently activated in pancreatic 
cancer and implicated in the disease phenotype. Moreover, numerous studies have 
indicated signaling cross-talk between EGFR, c-Src, and Stat3. In that context, it is 
conceived that the signaling cross-talk between the three entities would in part account 
for the poor clinical outcome of therapies that target only EGFR or Src alone. Present 
studies were intended to delineate the details of the inter-relationship between the 
EGFR, Src and Stat3 proteins and define the basis by which they support pancreatic 
cancer. Ultimately, these studies were to provide a molecular basis for designing an 
effective multiple-targeting therapy against the EGFR, Src and Stat3 pathways for 
pancreatic cancer. 
 
In defining the EGFR, Src, and Stat3 signaling and how it promotes and support 
pancreatic cancer, our studies show that Src activity contributes to the induction of 
EGFR activation, while both EGFR and Src activities promote constitutive Stat3 
activation. Our studies further show surprisingly that prolonged inhibition of EGFR and 
Src, which induced initial inhibition of constitutively-active Stat3, results in the induction 
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of a JAK-Stat3 activation as a secondary event. Due to this complexity, the inhibition of 
EGFR, Src or Stat3 alone had moderate antitumor cell effects on pancreatic cancer 
cells in vitro. By contrast, our studies show that the concurrent inhibition of Stat3 and 
EGFR, Stat3 and Src, or EGFR and Stat3 was more effective and significantly 
suppresses pancreatic cancer cell proliferation and viability, induced apoptosis, and 
inhibited migration and invasion in vitro. Moreover, the combined inhibition of Stat3 and 
EGFR, or Stat3 and Src inhibited growth of human pancreatic cancer in xenografts 
models. Our study thus presents a novel, more effective therapeutic modality. 
 
Additional studies to define details of the molecular interactions showed that the EGFR, 
Src and Stat3 proteins are physically associated into a heteromeric complex. 
Significantly, the EGFR, Src and Stat3 complex is detected in the nucleus of pancreatic 
cancer cells and not the normal human pancreatic duct epithelial cells. Moreover, our 
findings reveal that the EGFR, Src and Stat3 heteromeric complex is associated with 
and induces the c-Myc promoter, and the concurrent inhibition of Stat3 and EGFR, 
Stat3 and Src or EGFR and Src dramatically suppresses c-Myc expression. While 
present study is consistent with previous reports of an induction by EGF of a functional 
nuclear EGFR-Stat3 complex, it is the first report of presence of an EGFR-Src-Stat3 
heteromeric complex in the nucleus of pancreatic cancer cells. The incidence of the 
EGFR, Src, and Stat3 heteromeric complex and its association with the c-Myc promoter 
suggests the heteromeric complex may represent a novel mechanism for regulating 
gene expression in support of the pancreatic cancer phenotype. The complexity in the 
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signaling pathways and its regulation of critical cancer-relevant genes would explains 
the poor responsiveness of pancreatic cancer cells to treatments that only inhibit EGFR, 
or Src, while providing the rationale and support for combination approaches that target 
Stat3 and EGFR, Stat3 and Src. Moreover, the presence of a functional EGFR, Src and 
Stat3 heteromeric complex in the nucleus defines a new paradigm of Stat3-mediated 
gene transcription in the context of cancer. Although the present studies identifies key 
peptide motifs of the EGFR and Stat3 that might important for the complex formation, 
the results also provide basis to pursue further characterize the heteromeric complex, in 
terms of determining the specific domains of each protein that mediates the interaction, 
determine whether the complex contains other proteins in addition to EGFR, Src and 
Stat3, and how the proteins are physically associated. Moreover, while the present 
since further provides data to indicate Src in important in promoting pancreatic cancer 
cell migration, the molecular details of how Src induces cytoskeletal rearrangement to 
promote the migration of pancreatic cancer cells remain to be determined. 
 
 
  
85 
 
REFERENCES 
1. Jemal, A., et al., Cancer statistics, 2007. CA Cancer J Clin, 2007. 57(1): p. 43-66. 
2. Sakorafas, G.H. and A.G. Tsiotou, Multi-step pancreatic carcinogenesis and its clinical 
implications. Eur J Surg Oncol, 1999. 25(6): p. 562-5. 
3. Almoguera, C., et al., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras 
genes. Cell, 1988. 53(4): p. 549-54. 
4. Torrisani, J. and L. Buscail, [Molecular pathways of pancreatic carcinogenesis]. Ann Pathol, 
2002. 22(5): p. 349-55. 
5. Longo, R., et al., Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol 
Hematol, 2008. 68(3): p. 197-211. 
6. Burris, H., 3rd and C. Rocha-Lima, New therapeutic directions for advanced pancreatic 
cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. 
Oncologist, 2008. 13(3): p. 289-98. 
7. Di Renzo, M.F., et al., Expression of the Met/hepatocyte growth factor receptor in human 
pancreatic cancer. Cancer Res, 1995. 55(5): p. 1129-38. 
8. Mitsudomi, T. and Y. Yatabe, Epidermal growth factor receptor in relation to tumor 
development: EGFR gene and cancer. FEBS J. 277(2): p. 301-8. 
9. Papageorgio, C. and M.C. Perry, Epidermal growth factor receptor-targeted therapy for 
pancreatic cancer. Cancer Invest, 2007. 25(7): p. 647-57. 
10. Buerger, C., et al., Sequence-specific peptide aptamers, interacting with the intracellular domain 
of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of 
tumor cells. J Biol Chem, 2003. 278(39): p. 37610-21. 
11. Mueller, K.L., et al., Met and c-Src cooperate to compensate for loss of epidermal growth factor 
receptor kinase activity in breast cancer cells. Cancer Res, 2008. 68(9): p. 3314-22. 
12. Kannangai, R., F. Sahin, and M.S. Torbenson, EGFR is phosphorylated at Ty845 in 
hepatocellular carcinoma. Mod Pathol, 2006. 19(11): p. 1456-61. 
13. Ray, R.M., S. Bhattacharya, and L.R. Johnson, EGFR plays a pivotal role in the regulation of 
polyamine-dependent apoptosis in intestinal epithelial cells. Cell Signal, 2007. 19(12): p. 2519-
27. 
14. Wu, W., et al., Src-dependent phosphorylation of the epidermal growth factor receptor on 
tyrosine 845 is required for zinc-induced Ras activation. J Biol Chem, 2002. 277(27): p. 24252-
7. 
15. Belsches, A.P., M.D. Haskell, and S.J. Parsons, Role of c-Src tyrosine kinase in EGF-induced 
mitogenesis. Front Biosci, 1997. 2: p. d501-18. 
16. Irby, R.B. and T.J. Yeatman, Role of Src expression and activation in human cancer. 
Oncogene, 2000. 19(49): p. 5636-42. 
17. Ishizawar, R. and S.J. Parsons, c-Src and cooperating partners in human cancer. Cancer Cell, 
2004. 6(3): p. 209-14. 
18. Rucci, N., M. Susa, and A. Teti, Inhibition of protein kinase c-Src as a therapeutic approach for 
cancer and bone metastases. Anticancer Agents Med Chem, 2008. 8(3): p. 342-9. 
86 
 
19. Summy, J.M. and G.E. Gallick, Src family kinases in tumor progression and metastasis. 
Cancer Metastasis Rev, 2003. 22(4): p. 337-58. 
20. Lowery, M. and E.M. O'Reilly, Targeted therapies for pancreatic adenocarcinoma. Minerva 
Chir, 2009. 64(5): p. 501-19. 
21. Siddiquee, K., et al., Selective chemical probe inhibitor of Stat3, identified through structure-
based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A, 2007. 104(18): 
p. 7391-6. 
22. Shao, H., et al., Identification and characterization of signal transducer and activator of 
transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res, 2003. 
63(14): p. 3923-30. 
23. Tzeng, C.W., et al., EGFR genomic gain and aberrant pathway signaling in pancreatic cancer 
patients. J Surg Res, 2007. 143(1): p. 20-6. 
24. Korc, M., P. Meltzer, and J. Trent, Enhanced expression of epidermal growth factor receptor 
correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U 
S A, 1986. 83(14): p. 5141-4. 
25. Lutz, M.P., et al., Overexpression and activation of the tyrosine kinase Src in human pancreatic 
carcinoma. Biochem Biophys Res Commun, 1998. 243(2): p. 503-8. 
26. Tice, D.A., et al., Mechanism of biological synergy between cellular Src and epidermal growth 
factor receptor. Proc Natl Acad Sci U S A, 1999. 96(4): p. 1415-20. 
27. Trevino, J.G., et al., Src activation of Stat3 is an independent requirement from NF-kappaB 
activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. 
Angiogenesis, 2006. 9(2): p. 101-10. 
28. DeArmond, D., et al., Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for 
growth factor independence of pancreatic cancer cell lines. Oncogene, 2003. 22(49): p. 7781-95. 
29. Scholz, A., et al., Activated signal transducer and activator of transcription 3 (STAT3) supports 
the malignant phenotype of human pancreatic cancer. Gastroenterology, 2003. 125(3): p. 891-
905. 
30. Toyonaga, T., et al., Blockade of constitutively activated Janus kinase/signal transducer and 
activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett, 
2003. 201(1): p. 107-16. 
31. Darnell, J.E., Validating Stat3 in cancer therapy. Nat Med, 2005. 11(6): p. 595-6. 
32. Turkson, J., STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther 
Targets, 2004. 8(5): p. 409-22. 
33. Yue, P. and J. Turkson, Targeting STAT3 in cancer: how successful are we? Expert Opin 
Investig Drugs, 2009. 18(1): p. 45-56. 
34. Saif, M.W., Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opin 
Pharmacother, 2008. 9(9): p. 1595-607. 
35. Turkson, J., et al., Stat3 activation by Src induces specific gene regulation and is required for 
cell transformation. Mol Cell Biol, 1998. 18(5): p. 2545-52. 
87 
 
36. Garcia, R., et al., Constitutive activation of Stat3 by the Src and JAK tyrosine kinases 
participates in growth regulation of human breast carcinoma cells. Oncogene, 2001. 20(20): p. 
2499-513. 
37. Huang, M., et al., Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive 
activation of Stat5 and growth of CML cells. Oncogene, 2002. 21(57): p. 8804-16. 
38. Ouyang, H., et al., Immortal human pancreatic duct epithelial cell lines with near normal 
genotype and phenotype. Am J Pathol, 2000. 157(5): p. 1623-31. 
39. Wagner, B.J., et al., The SIF binding element confers sis/PDGF inducibility onto the c-fos 
promoter. EMBO J, 1990. 9(13): p. 4477-84. 
40. Seidel, H.M., et al., Spacing of palindromic half sites as a determinant of selective STAT (signal 
transducers and activators of transcription) DNA binding and transcriptional activity. Proc 
Natl Acad Sci U S A, 1995. 92(7): p. 3041-5. 
41. Gouilleux, F., et al., Prolactin and interleukin-2 receptors in T lymphocytes signal through a 
MGF-STAT5-like transcription factor. Endocrinology, 1995. 136(12): p. 5700-8. 
42. Zhang, Y., et al., Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of 
Jak1 kinase activity. J Biol Chem, 2000. 275(32): p. 24935-44. 
43. Zhao, S., et al., Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming 
growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res, 
2008. 68(11): p. 4221-8. 
44. Siddiquee, K.A., et al., An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 
stability and processing and induces antitumor cell effects. ACS Chem Biol, 2007. 2(12): p. 
787-98. 
45. Downward, J., P. Parker, and M.D. Waterfield, Autophosphorylation sites on the epidermal 
growth factor receptor. Nature, 1984. 311(5985): p. 483-5. 
46. Nam, S., et al., Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human 
prostate cancer cells. Cancer Res, 2005. 65(20): p. 9185-9. 
47. Mahtouk, K., et al., Expression of EGF-family receptors and amphiregulin in multiple myeloma. 
Amphiregulin is a growth factor for myeloma cells. Oncogene, 2005. 24(21): p. 3512-24. 
48. Wakeling, A.E., et al., ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor 
signaling with potential for cancer therapy. Cancer Res, 2002. 62(20): p. 5749-54. 
49. Johnson, F.M., et al., Abrogation of signal transducer and activator of transcription 3 
reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res, 
2007. 13(14): p. 4233-44. 
50. Philip, P.A., Targeted therapies for pancreatic cancer. Gastrointest Cancer Res, 2008. 2(4 
Suppl): p. S16-9. 
51. Senderowicz, A.M., et al., Erlotinib/gemcitabine for first-line treatment of locally advanced or 
metastatic adenocarcinoma of the pancreas. Oncology (Williston Park), 2007. 21(14): p. 1696-
706; discussion 1706-9, 1712, 1715. 
52. Salomon, D.S., et al., Epidermal growth factor-related peptides and their receptors in human 
malignancies. Crit Rev Oncol Hematol, 1995. 19(3): p. 183-232. 
88 
 
53. Dong, M., et al., Epidermal growth factor and its receptor as prognostic indicators in Chinese 
patients with pancreatic cancer. Anticancer Res, 1998. 18(6B): p. 4613-9. 
54. Ueda, S., et al., The correlation between cytoplasmic overexpression of epidermal growth factor 
receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal 
adenocarcinoma. Pancreas, 2004. 29(1): p. e1-8. 
55. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2): p. 211-25. 
56. Ullrich, A. and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity. 
Cell, 1990. 61(2): p. 203-12. 
57. Liu, L., K.M. McBride, and N.C. Reich, STAT3 nuclear import is independent of tyrosine 
phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A, 2005. 102(23): p. 
8150-5. 
58. Kawashima, T., et al., A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing 
signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell 
Biol, 2009. 29(7): p. 1796-813. 
59. Bild, A.H., J. Turkson, and R. Jove, Cytoplasmic transport of Stat3 by receptor-mediated 
endocytosis. EMBO J, 2002. 21(13): p. 3255-63. 
60. Sehgal, P.B., et al., Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem, 2002. 
277(14): p. 12067-74. 
61. Lin, S.Y., et al., Nuclear localization of EGF receptor and its potential new role as a 
transcription factor. Nat Cell Biol, 2001. 3(9): p. 802-8. 
62. Lo, H.W., S.C. Hsu, and M.C. Hung, EGFR signaling pathway in breast cancers: from 
traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat, 
2006. 95(3): p. 211-8. 
63. Lo, H.W., et al., Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO 
pathway. Cancer Cell, 2005. 7(6): p. 575-89. 
64. Trevino, J.G., et al., Inhibition of SRC expression and activity inhibits tumor progression and 
metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J 
Pathol, 2006. 168(3): p. 962-72. 
65. Jaganathan, S., P. Yue, and J. Turkson, Enhanced sensitivity of pancreatic cancer cells to 
concurrent inhibition of aberrant signal transducer and activator of transcription 3 and 
epidermal growth factor receptor or Src. J Pharmacol Exp Ther. 333(2): p. 373-81. 
66. Chou, C.K., et al., High speed digital protein interaction analysis using microfluidic single 
molecule detection system. Lab Chip. 10(14): p. 1793-8. 
67. Turkson, J., et al., Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene 
regulation, and cell transformation. J Biol Chem, 2001. 276(48): p. 45443-55. 
68. Bowman, T., et al., STATs in oncogenesis. Oncogene, 2000. 19(21): p. 2474-88. 
69. Coffer, P.J. and W. Kruijer, EGF receptor deletions define a region specifically mediating STAT 
transcription factor activation. Biochem Biophys Res Commun, 1995. 210(1): p. 74-81. 
70. Darnell, J.E., Jr., STATs and gene regulation. Science, 1997. 277(5332): p. 1630-5. 
71. Zhao, W., S. Jaganathan, and J. Turkson, A cell permeable Stat3 SH2 domain mimetic inhibits 
Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem. 
89 
 
72. Hsu, S.C. and M.C. Hung, Characterization of a novel tripartite nuclear localization sequence 
in the EGFR family. J Biol Chem, 2007. 282(14): p. 10432-40. 
73. Lo, H.W., et al., Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin 
beta1 and CRM1. J Cell Biochem, 2006. 98(6): p. 1570-83. 
74. Dai, Q., et al., A one-step highly sensitive method for DNA detection using dynamic light 
scattering. J Am Chem Soc, 2008. 130(26): p. 8138-9. 
75. Huo, Q., Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle 
aggregation immunoassay. Colloids Surf B Biointerfaces. 78(2): p. 259-65. 
76. Jans, H., et al., Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation 
and biomolecular binding studies. Anal Chem, 2009. 81(22): p. 9425-32. 
77. Liu, X., et al., A one-step homogeneous immunoassay for cancer biomarker detection using gold 
nanoparticle probes coupled with dynamic light scattering. J Am Chem Soc, 2008. 130(9): p. 
2780-2. 
78. Liu, X. and Q. Huo, A washing-free and amplification-free one-step homogeneous assay for 
protein detection using gold nanoparticle probes and dynamic light scattering. J Immunol 
Methods, 2009. 349(1-2): p. 38-44. 
79. Jimeno, A., et al., Coordinated epidermal growth factor receptor pathway gene overexpression 
predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res, 
2008. 68(8): p. 2841-9. 
80. Turkson, J. and R. Jove, STAT proteins: novel molecular targets for cancer drug discovery. 
Oncogene, 2000. 19(56): p. 6613-26. 
81. Thelemann, A., et al., Phosphotyrosine signaling networks in epidermal growth factor receptor 
overexpressing squamous carcinoma cells. Mol Cell Proteomics, 2005. 4(4): p. 356-76. 
82. Grivennikov, S.I. and M. Karin, Dangerous liaisons: STAT3 and NF-kappaB collaboration and 
crosstalk in cancer. Cytokine Growth Factor Rev. 21(1): p. 11-9. 
83. Yang, J., et al., Unphosphorylated STAT3 accumulates in response to IL-6 and activates 
transcription by binding to NFkappaB. Genes Dev, 2007. 21(11): p. 1396-408. 
84. Niu, G., et al., Constitutive Stat3 activity up-regulates VEGF expression and tumor 
angiogenesis. Oncogene, 2002. 21(13): p. 2000-8. 
85. Sinibaldi, D., et al., Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src 
oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene, 2000. 19(48): p. 
5419-27. 
86. Liao, H.J. and G. Carpenter, Role of the Sec61 translocon in EGF receptor trafficking to the 
nucleus and gene expression. Mol Biol Cell, 2007. 18(3): p. 1064-72. 
87. Ndubuisi, M.I., et al., Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol 
Chem, 1999. 274(36): p. 25499-509. 
88. Guo, G.G., et al., Association of the chaperone glucose-regulated protein 58 (GRP58/ER-
60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J Interferon Cytokine Res, 
2002. 22(5): p. 555-63. 
90 
 
89. Biscardi, J.S., et al., c-Src-mediated phosphorylation of the epidermal growth factor receptor on 
Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem, 1999. 
274(12): p. 8335-43. 
90. Cao, X., et al., Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol 
Cell Biol, 1996. 16(4): p. 1595-603. 
91. Lo, H.W., et al., Novel prognostic value of nuclear epidermal growth factor receptor in breast 
cancer. Cancer Res, 2005. 65(1): p. 338-48. 
92. Xia, W., et al., Nuclear expression of epidermal growth factor receptor is a novel prognostic 
value in patients with ovarian cancer. Mol Carcinog, 2009. 48(7): p. 610-7. 
93. Messersmith, W.A., et al., Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a 
Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther, 
2009. 8(6): p. 1484-93. 
94. Nagaraj, N.S., et al., Targeted inhibition of SRC kinase signaling attenuates pancreatic 
tumorigenesis. Mol Cancer Ther. 9(8): p. 2322-32. 
95. Ricono, J.M., et al., Specific cross-talk between epidermal growth factor receptor and integrin 
alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res, 2009. 69(4): p. 1383-
91. 
96. Narumiya, S., M. Tanji, and T. Ishizaki, Rho signaling, ROCK and mDia1, in transformation, 
metastasis and invasion. Cancer Metastasis Rev, 2009. 28(1-2): p. 65-76. 
97. Narumiya, S., M. Tanji, and T. Ishizaki, Rho signaling, ROCK and mDia1, in transformation, 
metastasis and invasion. Cancer Metastasis Rev. , 2009. 28 p. 66-76. 
98. Zhang, X., et al., A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine 
interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 79(10): p. 1398-409. 
 
 
